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ABSTRACT OF DISSERTATION

ROLE OF VIRAL AND HOST FACTORS IN INFLUENZA VIRUS MEDIATED
INHIBITION OF INTERLEUKIN-23
Influenza virus is one of the major respiratory pathogens of humans as well as
animals, including equines. There is an increasing evidence that bacterial infections are the
most common cause of the death during influenza. In horses also, secondary bacterial
pneumonia can lead to death, and surviving horses may take up to six months for the
complete recovery resulting in heavy economic loss to the equine industry. Interleukin
(IL)-23 mediated innate immune response has been shown to protect the host from various
respiratory bacterial infections. However, studies to investigate the role of host and viral
factors in the regulation of IL-23 are limited. Endoplasmic reticulum (ER) stress-induced
transcription factor CHOP-10 and IFN-β has been shown to participate in the regulation of
IL-23. Primary hypothesis for the current study was that influenza A virus (IAV) NS1
protein downregulates the IL-23 expression via inhibition of CHOP-10. In order to test our
hypothesis, we infected the RAW264.7 cells - a murine macrophage cell line, and primary
murine alveolar macrophage cells either with the wild type Influenza A virus (PR/8/34,
PR8) or isogenic mutant virus lacking NS1 (delNS1). Quantitative analysis of mRNA
expression revealed a significantly higher mRNA expression of IL23p19, IFN-β and
CHOP-10 in delNS1 virus infected cells as compared the PR8 virus infected cells.
Additionally, overexpression of CHOP-10 partially restored the expression of IL-23p19 in
PR8 virus infected cells and knockdown of CHOP-10 resulted in downregulated expression
of IL-23p19 in delNS1 infected cells. Taken together, these results suggest that IAV NS1
protein mediated inhibition of CHOP-10 expression leads to downregulation of IL-23
expression in macrophage cells in-vitro. Similar results were also observed in-vivo using
IAV and Streptococcus zoooepidemicus (S. ze) co-infection model. In a co-infection mouse
model delNS1 virus co-infection resulted in significantly higher expression of the IL-23
and IL-17. Considering the role of IL-23 in protection against respiratory bacterial
pathogens, effect of exogenous supplementation of IL-23 was also investigated in the
influenza and S. ze co-infection mouse model. We found that a single intranasal dose of
recombinant murine IL-23 significantly improved the survival of mice co-infected with
PR8 and S .ze. Overall, our study suggests that IAV infection subverts the IL-23 mediated
respiratory innate immune response and restoration of IL-23 could protect from influenzaassociated respiratory bacterial infections.
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CHAPTER 1
Introduction and hypothesis
1.1. Introduction
Influenza is one of the most common viral respiratory disease of birds, humans, and
animals including horses and is caused by influenza A virus (IAV). Each year, recurrent
epidemics of influenza, commonly called seasonal influenza, result in 3-5 million severe
cases and 250,000-500,000 deaths worldwide, leading to significant economic losses.
Occasional pandemics further add to the quandary. Secondary bacterial infections were
suggested to be major contributors in the pathology and mortality associated with human
influenza almost a century ago and confirmed later [1]. Similarly, secondary bacterial
infections are not uncommon in equine influenza. Despite significant progress in
understanding the pathogenesis of influenza and the mechanism of influenza and bacterial
synergy, bacterial co-infections still remain the major factor in determining the outcome of
influenza. Therefore, the current study was designed to explore the possible mechanism
that could contribute to increased susceptibility to secondary bacterial infection during
influenza.
The first hypothesis was that influenza virus mediated inhibition of IL-23 leads to
enhance susceptibility of the host to secondary bacterial infections. Cytokines are integral
parts of the innate immune system, a broadly reactive defense mechanism which acts as
the first line of defense against a variety of invading pathogens. Interleukin (IL)-23 is a
recently identified cytokine that has been shown to be important in the respiratory innate
immune response. Interleukin (IL)-23, in concert with IL-17, constitutes a newly identified
innate immune pathway. The host IL-23/IL-17 pathway has been shown to play a critical
1

role in the clearance of many respiratory bacterial pathogens [2]. However, its role during
influenza and bacterial co-infection has not been investigated. Thus, it was hypothesized
that inhibition of respiratory IL23/IL17 pathway by influenza virus predisposes the host to
secondary bacterial infection.
The second hypothesis was that influenza virus inhibits the expression of
endoplasmic reticulum (ER) stress induced transcription factors. ER stress response, also
called the unfolded protein response (UPR), is an evolutionary molecular cascade to
maintain ER homeostasis and the protein folding capacity of the ER. However, recent
studies implicate the ER stress response in other cellular and disease processes such as
apoptosis and inflammation [3]. Since viruses rely heavily on the host cell protein
synthesis machinery, the functional status of the ER may significantly affect viral
replication and pathogenesis. Differential activation of ER stress pathways has been shown
for multiple viruses including influenza. However, viral factors responsible for differential
activation of ER stress response in influenza-infected cells are not known. C/EBP
homologous protein-10 (CHOP-10) is one of the key mediators of ER stress. During
prolonged ER stress, CHOP-10 mediates cell death by apoptosis. Although apoptosis could
help in the pathogenesis of the virus, it could also prematurely terminate viral replication.
CHOP-10 also acts as a transcription factor for several other genes. In human dendritic
cells (DCs), induction of CHOP-10 was critical in IL-23 expression [4]. Therefore, it was
hypothesized that influenza virus inhibits the CHOP-10.
The next hypothesis for the study was that influenza virus NS1 protein was the viral
factor that mediates the inhibition of CHOP-10. In order to reduce the protein load during
ER stress, eukaryotic initiation factor-2 alpha (eIF2-α) is phosphorylated to shut down
2

global protein synthesis in the cell. Two major cellular kinases, double-stranded-RNA
(dsRNA)-activated protein kinase (PKR) and PKR-like ER kinase (PERK), are important
in the phosphorylation of eIF2-α. Influenza virus NS1 is known to inhibit PKR that also
results in inhibition of type-I interferons (IFN). Additionally, influenza virus infection has
been found to not to activate PERK. Phosphorylation of eIF2-α, also leads to selective
transcription of activating transcription factor 4 (ATF4) that leads to induction of CHOP10. Inhibition of the kinases thus may favor influenza virus replication in two ways- I) by
allowing viral proteins to be synthesized before the IFN response shuts down cellular
protein synthesis; II) by delaying the onset of apoptosis induced by the endoplasmic
reticulum (ER) stress-induced transcription factor CHOP-10. Therefore, it was
hypothesized that influenza virus NS1 inhibits the expression of CHOP-10.
1.2. Hypothesis
Influenza virus NS1 protein mediated inhibition of CHOP-10 leads to an impaired
IL-23/IL-17 immune pathway in the lungs and causes increased susceptibility to secondary
bacterial infections.
1.3. Research objectives
In order to test the above hypothesis the study is performed with following objectives
1. Determine the effect of influenza virus on ER stress
2. Determine the effect of NS1 mediated CHOP-10 inhibition on IL-23
expression
3. Determine the effect of restoration of respiratory IL-23 on pathogenesis of
influenza

3

Macrophages are important components of host innate immune defense. Besides
DCs, macrophage cells are the only cells that secrete biologically active IL-23 [5].
Therefore, the hypothesis was tested in macrophage cells in vitro and in a mouse model in
vivo. The overreaching goal of the study was to investigate role of the IL-23/IL-17 pathway
in the horse. However, a mouse model for influenza as well as co-infection has been well
established using the PR8 virus. Although there are areas that need further investigation,
results of this dissertation provide evidence to support the major hypotheses. Secondary
bacterial infections, similar to human influenza, are also common in equine influenza and
it is possible that IL-23/IL17 pathway could be a general mechanism that leads to increased
susceptibility during influenza and these results could be applied to equine influenza.

Copyright © Ashish Tiwari 2014
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CHAPTER 2
Literature review
Influenza viruses are negative-sense single-stranded, segmented RNA genome
viruses of family Orthomyxoviridae. The family Orthomyxoviridae consists of five, wellcharacterized genera, including

Influenzavirus A, Influenzavirus B, Influenzavirus C,

Isavirus and Thogotovirus, and recently discovered, still undescribed, sixth genus [6]. Each
genus of influenza virus has one species or type - Influenza A virus, Influenza B virus and
Influenza C virus, respectively. These three genera can be distinguished by antigenic
differences in their nucleoprotein and matrix protein. Among the three types, only
influenza A viruses (IAV) are further subtyped based on their surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA). All three influenza viruses can infect
mammals. Whereas influenza B viruses have been shown to infect humans and seals and
influenza C viruses infect human and pigs, IAVs can infect various mammals including
equine.
2.1. Influenza A virus
IAV is the primary etiological agent of a highly contagious, acute respiratory
disease of humans and animals that follows recurring seasonal epidemics of high morbidity
and mortality, as well as worldwide pandemics. On the basis of two surface glycoproteinsHA and NA- influenza a viruses have been further subtyped into 16 well established HA
subtypes and 9 NA subtype [7]. Recently, a 17th HA subtype has been identified from little
yellow-shouldered bats captured at two locations in Guatemala. However, attempts of virus
isolation in either cell culture or chicken embryos were unsuccessful [8]. Wild aquatic bird
such as- waterfowl, duck, geese, swan, gulls, terns, etc. - are the natural reservoirs for all
5

the subtypes of IAV. In the wild aquatic birds, the virus is benignly adapted and does not
cause symptomatic infection. In these reservoir hosts, virus is considered to be in an
evolutionary stasis that establishes a perpetual viral gene pool. Different subtypes of IAV,
however, have successfully jumped from their natural reservoir hosts to other avian and
mammalian hosts and caused clinical disease [9].
2.2. Viral genome and encoded proteins
The genome of influenza virus is about 13.6 kb and consists of eight singlestranded, negative-sense RNA molecules. Each RNA segment is encapsidated with several
nucleocapsid protein (NP) molecules forming a flexible rod-shaped ribonucleoprotein
(RNP) that also has three viral polymerase protein- basic polymerase 1(PB1), basic
polymerase 2 (PB2) and acidic polymerase (PA)- associated at the end of RNP [10]. The
eight genome segments of influenza virus encode for the ten proteins of influenza virus
(HA, NA, PB1, PB2, PA, NP, NS1, NS2, M1 and M2) that are found in all IAV. In addition
to PB1, gene segment 2 also encodes another protein PB1-F2 that localizes to mitochondria
and has been implicated in cellular apoptosis. Recently, an additional protein N40, an Nterminal truncated version of PB1, was discovered to be translated from fifth AUG codon
(codon 40) of PB1 [11]. In 2012, PA-X, another new protein of IAV, was discovered which
is synthesized from segment three that primarily encodes PA [12].
2.2.1. The surface glycoproteins
Influenza virus encodes two surface glycoproteins-HA and NA that have important
roles in the host range, viral replication, and pathogenicity.

6

Hemagglutinin (HA)
Hemagglutinin is membrane glycoprotein (MW 61.5 kDa monomer) and the major
surface antigen of influenza virus encoded by the fourth largest gene (1778 nucleotides) of
the viral genome. The HA molecule is synthesized as homotrimeric spike of non-covalently
linked monomers in the rough endoplasmic reticulum of the infected cells [13]. Native HA
is synthesized as a single polypeptide (HA0) that is processed into two disulfide-linked
subunits referred as HA1 and HA2. Depending on the strain, the cleavage of HA0 is carried
out either by ubiquitously distributed furin proteases or tissue specific proteases such as
trypsin [14] and HA cleavage is a crucial determinant of viral pathogenicity [14]. Influenza
virus HA has two important functions- (I) facilitate viral attachment by binding to sialic
acid-containing receptors on the host cell, and (II) mediate fusion between the endocytic
vesicle and viral membrane during penetration, enabling release of the viral genome into
the cytoplasm. Being a surface antigen, HA is also under constant immune selection
pressure. Thus, mutations in HA may allow the virus to escape neutralizing antibodies by
antigenic drift [15].
Neuraminidase (NA)
The NA gene (1461 nucleotides) of influenza virus encodes for neuraminidase
protein -the second surface glycoprotein of influenza virus. The NA molecule is
synthesized as a 454 amino acid (aa) monomer that oligomerizes to form a mushroom
shaped trimeric protein. While the N-terminal stalk of NA anchors it to the viral membrane,
the box-shaped head contains enzymatic activity to catalyze the cleavage of sialic acid [16].
The NA protein-mediated enzymatic cleavage of sialic acid from cell surfaces is critical
for the release of progeny virus during the viral replication cycle. Additionally, it also
7

removes sialic acid residues from the carbohydrates on viral membrane glycoproteins and
prevents virus self-aggregation [17]. Although NA does not have any direct role in the
attachment, NA could also remove mucins and facilitate virus access to the epithelial cells
[18]. NA has also been implicated in facilitating a secondary bacterial infection that will
be discussed later in this chapter.
2.2.2. Polymerase proteins
The PB1, PB2 and PA proteins together form the polymerase complex of the
influenza virus that provides RNA-dependent RNA polymerase activity for the virus [19,
20].The proteins are named on the basis of their isoelectric properties: whereas PB1 and
PB2 are basic proteins PA is an acidic protein.
PB1 is a 96.5 kDa basic subunit of the polymerase complex encoded by segment 2
(2270 nucleotides) and serves as a backbone that can bind to the two other subunits of the
polymerase complex as well as to NP (SB 18, 19). PB1 is a catalytically active subunit of
RNA-dependent RNA polymerase that is involved in initiation and elongation of mRNA,
complementary RNA (cRNA), and genomic RNA, in a sequence-specific manner [21, 22].
PB1, by endonucleolytic cleavage of cellular mRNA, also generates capped RNA primers
for initiation of viral mRNA synthesis [23].
The coding region (2275 nucleotides) of genomic RNA segment 1 of influenza
virus encodes the second basic subunit (PB2) of viral polymerase complex. The PB2
protein binds to the 5’-cap structure (m7GpppNm) of host cell pre-mRNA, which is later
cleaved in a process called “cap snatching,” to prime viral mRNA synthesis.
Encoded by the segment 3 (2150 nucleotide coding region) of the influenza virus
genome, PA is the third and the only acidic subunit of the viral polymerase complex. When
8

expressed individually, PA demonstrates proteolytic activity that affects co-expressed
proteins and PA itself [24]. However, its specific roles in viral transcription and replication
are poorly defined [24-26].
2.2.3. Nucleoprotein (NP)
The NP gene (1565 nucleotides) encodes a highly basic, single-stranded RNA
binding protein with a molecular weight of 56.1 kDa. Nucleoprotein is the second most
abundant protein of virion. After synthesis and post-translational phosphorylation in the
cytoplasm, NP is transported into the nucleus of host cells where it binds to newly
synthesized viral RNA [27, 28] and provides structural organization to the RNP complex.
NP also interacts with other viral proteins including the viral polymerase proteins (PB1 and
PB2) and the matrix proteins (M1) [29-31]. Interaction with cellular proteins such as
importin –α, F-actin, CRM1, BAT/UAP56 and MX has also been observed. Whereas
interaction of NP with importin-α, F-actin and CRM1 is critical for intracellular trafficking
of RNP complexes [32-34], interaction with BAT1/UAP56 and MX protein up- and downregulates viral RNA synthesis, respectively [35, 36]. NP is also a major target of immune
cells as cytotoxic T lymphocytes non-specifically cross react with NP of all influenza virus
subtypes [37].
2.2.4. Matrix protein
The M gene (1027 nucleotides) of influenza virus, by alternative splicing of
overlapping reading frames, encodes two viral structural proteins- matrix protein 1 and 2
(M1 and M2). M1 is the most abundant protein present underlying the viral envelope. M1
is also suggested to interact with the cytoplasmic tails of HA and NA molecules [38]. M1
binds to the RNP through its C-terminal domain to facilitate their nuclear-cytoplasmic
9

transport [39, 40]. It also has critical roles in recruitment and assembly of viral and host
components for the budding of the virus [41]. M2 protein is a type-III integral membrane
protein with a short ectodomain, a transmembrane domain, and a cytoplasmic tail [42]. It
forms a tetrameric proton channel that allows the acidification of the interior of the virion
from the acidified endosomes leading to critical conformational changes and uncoating of
the viral RNP complex. Therefore, M2 ion channel blockers have been used as influenza
virus replication inhibitors.
2.2.5. Nonstructural proteins
Segment eight of the influenza viral genome is the smallest gene (890 nucleotides)
and encodes two nonstructural protein- NS1 and NS2. The NS1 protein has a molecular
mass of approximately 26 KDa and a strain-specific length of 230-237 aa [43]. However,
a C-terminal truncated (15-30 aa) NS1 protein also exists in nature [44]. The NS1 protein
of IAVs can be divided into two distinct functional domains. The N-terminal RNA-binding
domain (RBD) consist of residues 1-73 that in vitro binds with low affinity to various
RNA molecules in a sequence-independent manner [45, 46]. Residues 74-230 of NS1
protein form the C-terminal effector domain (ED) that mediates interaction with cellular
proteins of the host, and also helps in stabilization of the RNA-binding domain [47].
Within host cells, functional NS1 exists as a homodimer stabilized by interaction between
both the N-terminal RBD and C-terminal ED of NS1 [48]. Homodimerization of the RBD
is also essential for its RNA binding function. A double-stranded RNA –binding pocket is
formed by two antiparallel tracks of basic and hydrophilic residues from identical α-helices
on either side of a deep cleft from two NS1 subunits [49]. Assembly of the dimeric-NS1
effector domain has not been completely understood. Based on the crystal structure of
10

human NS1 allele A, a strand-strand model that consisted of two NS1 effector domain
monomers made up of seven β-strands and three α-helices was proposed [50]. In this
model, each monomer β-sheet forms a crescent shape twisted structure around the central
α-helix [50]. On the other hand, Hale at al., 2008 [51], proposed a helix-helix model and
observed that a tryptophan residue located at the interface of monomers was critical for
dimerization of the effector domain. However, it is important to note that effector domain
structure published by Hale et al., was for an avian influenza virus allele B NS1, whereas
the model by Bornholdt and Prasad [50], was based on allele A of NS1 of human influenza
virus. Hence, it is conceivable that two alleles of NS1 might have a different structure and
might have a variable effect on pathogenicity of influenza viruses. Also, it should be noted
that full-length NS1 might have a different conformation, which might impact the functions
of NS1. To date only two studies are available on the structure of full-length NS1. A crystal
structure of H5N1 (A/Vietnam/1203/2004) NS1 was determined and it was found that NS1
forms a dimer through interaction of the RBD and two ED flank the RBD dimers. Also,
the two domains of NS1 interact separately with respective domains of alternating RBD
and ED dimers of neighboring NS1 molecules to form a higher-order chain like structure
[52]. It should be noted, however that H5-NS1 in this study contains a 5aa deletion in the
linker region and represents only a minority of influenza virus NS1. Recently, Carillo et
al., determined the structure of full length NS1 from an H6N6 IAV (A/blue-winged
teal/993/1980) that does not have five aa deletion, and thus may represent more common
form of NS1[53]. The authors also studied the effect of linker region (LR) mutations on
the three-dimensional structure of full-length NS1. The study revealed that length of the
linker, composition of residue 71 and the mechanical hinge are critical determinants in the
11

structure of full-length NS1. Full-length NS1, depending on the strain, can adopt different
structures. Depending on the orientation of the ED with respect to RBD there could be
three possible conformations as “open," semi-open and closed conformation that might
explain some of the strain variation in NS1 functions [53]. Although NS1 is not
incorporated into the virion, it is abundantly present in virus-infected cells and is one of
the most versatile protein of influenza virus. NS1 interacts with a variety of cellular
proteins and plays critical roles in the replication and pathogenesis of influenza virus
including inhibition of splicing and export of polyadenylated cellular mRNA cellular [54,
55], promoting translation of viral mRNA [56], and inhibiting cellular innate antiviral
pathways [57-62]. NS1 protein also inhibits maturation and migration of dendritic cells
resulting in dysfunctional T-cell stimulation and cytokine production [7]. The functions of
NS1 will be discussed in detail later in this chapter.
Unlike NS1, NS2/NEP (nuclear export protein), expressed from an alternatively
spliced mRNA of NS RNA segment, is incorporated in the virion in the phosphorylated
form [63]. NEP, in association with M1, facilitates the transport of viral RNP complex
from nucleus to the cytoplasm. NS2/NEP is also critical in the regulation of viral RNA
transcription and replication [64].
2.3. Replication of influenza virus
Replication of influenza A viruses is a multistage process that includes attachment,
entry, fusion and uncoating, genome transcription, viral protein synthesis, assembly and
finally egress/budding of progeny virions (Figure 2.1).
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2.3.1. Receptor binding and cell entry
Influenza virus attaches to sialic acid receptors through HA protein present on the
surface of the virion. Following receptor binding, virions are endocytosed into a cellular
compartment. Clathrin-mediated endocytosis is apparently major endocytic mechanism
[65], however, clathrin- independent mechanisms [66, 67], and macropinocytosis [68, 69]
has also been proposed for influenza virus internalization.
2.3.2. Membrane fusion and uncoating
The acidic pH of endosomal vesicles induces irreversible conformational changes
in the HA protein that causes the fusion peptide (HA2 subunit) to insert in to the endosomal
membrane. At this time, the M2 ion channel also facilitates acidification of interior of the
virus particle that leads to the release of the viral RNP complex. The viral RNP complex
consists of eight viral RNA segments wrapped around the nucleoprotein together with viral
polymerases [70]. Subsequently, viral RNP is transported into the nucleus in a process
mediated by nuclear localization signals on the nucleoprotein [71, 72].
2.3.3. RNA replication and translation
The trimeric viral polymerase complex, consisting of PB2, PB1 and PA subunits,
transcribes viral genomic RNAs in to mRNA by a cap-dependent manner using 5’ cap
structures derived from host mRNAs. Viral mRNAs derived from viral RNA segments M
and NS are alternatively spliced to generate M1, M2 and NS1, NEP/NS2, respectively.
Although host cell machinery performs the splicing, it is most likely regulated by NS1 [73,
74]. Translation of viral mRNAs is carried out by the host translation machinery, thus,
during IAV infection, host cell protein synthesis is limited and viral mRNA translation is
preferred [75-77]. Interaction of NS1 with cellular poly A binding protein II (PABII) [7813

80] and cleavage and polyadenylation specificity factor subunit 30 (CPSF30) [57, 81] has
been shown to be important in the inhibition of host mRNA synthesis.
2.3.4. Virus assembly and release
Following synthesis in the cytoplasm, viral proteins are transported back to the
nucleus where viral RNP complexes are formed and then exported out to the cytoplasm
mediated by M1 [82-84] and NEP/NS2 [85-88]. The ER has an important role in the
generation of mature influenza virions as it carries out important post translational
modifications such as glycosylation (HA, NA and M2) and palmitoylation (HA and M2)
of viral proteins [70]. Virus assembly requires transport of the viral proteins to the plasma
membrane likely mediated microtubule organizing centers (mTOCS) [89], microtubules
[89-91] and additional host factor that include coatomer I (COPI) proteins [92](147), Rab
GTPase (Rab11A) [93-95] and HIV rev Binding proteins (HRB) [90, 96]. The assembly
starts by association of HA and NA with lipid rafts at plasma membrane of the host cell
(152-160). Assembly involves incorporation of eight viral RNP dictated by segment
specific packaging signals in the viral RNAs (161, 162). The M1 and M2 proteins play
critical roles in packaging [97, 98]. Viral M2 protein and NA proteins are critical in
budding and release of the virions. The M2 protein, present in the raft periphery, mediates
cleavage and particle release [99]. The NA protein cleaves sialic acid from host cells, and
from the virion glycoproteins that leads to the virion release and prevents virion
aggregation, respectively [70]. Additionally, the ER serves as an important site of posttranslational modification of influenza viral proteins which could induce ER stress.
However, functional ER is important in the replication of influenza virus. It is evident that
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NS1, although not incorporated into the virion, plays critical roles in the regulation of
influenza virus replication.

Figure 2.1. Simplified schematic representation of influenza virus replication cycle

2.4. Host innate defense mechanisms against influenza
An immunocompetent host during influenza virus infection mounts a robust antiviral response to limit viral replication. Both, innate and adaptive immune systems
participate in containment and clearance of viral infection in about a week. The innate
immune response, not specific to the pathogen, is however the first and foremost barrier in
acute influenza infection. An emerging theory is that besides reducing the pathogen burden
(antiviral resistance), reducing the negative impact of infection on host fitness (disease
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tolerance) could significantly affect the outcome of infection [100]. While disease
resistance is important in controlling acute infections, disease tolerance can also protect the
host from some acute and chronic infections even when resistance mechanisms fail to
protect the host. In the case of infection of African green monkey and sooty mangabey with
simian immunodeficiency virus (SIV), for example, despite high viral burden, clinical
disease does not occur [101]. In the case of influenza and Legionella pneumophila coinfection impaired ability to tolerate tissue damage resulted in an increased susceptibility
to bacterial infection; and promoting the tissue repair with amphiregulin treatment resulted
in increased survival of the host without affecting the pathogen burden [102].
Innate immunity against influenza involves a concerted participation of various
strategies such as physical barriers, soluble factors and immune cells. Pattern recognition
receptor recognition of viral RNA as a foreign molecule leads to the secretion of type-I
IFN mainly from macrophages, pneumocytes, conventional DCs and plasmacytoid DCs
(pDCs) [103-105]. Type-I IFN, in turn, activates hundreds of genes collectively called IFNstimulated genes (ISGs), in nearby cells resulting in the antiviral state. Viral infection, in
addition to type-I IFN, also induces pro-inflammatory cytokine and chemokines.
Chemokines recruit additional immune cells including neutrophils, monocytes, and natural
killer (NK) cells to the lungs. Virally infected epithelial cells become the target of NK cells
that mediate viral clearance [106]. By phagocytizing the virus infected cells, in concert
with alveolar macrophages, recruited monocytes and neutrophils are an important
mechanism of viral clearance [107].
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2.4.1. Physical barriers
The respiratory epithelium is coated with large amounts of mucins that can trap the
invading viral or bacterial pathogens. While mucins trap the pathogen, concerted beating
of the broncho-pulmonary cilia expel the pathogen out of the airway. Loss of this
mucociliary escalator system is one of the mechanisms of influenza pathogenesis that can
pre-dispose the host to increased susceptibility to secondary infection [108].
2.4.2. Soluble antimicrobial factors
Pathogens that have successfully compromised the physical barrier are neutralized
by antimicrobial factors such as lysozymes, lactoferrin, and defensins. In humans, alphadefensins, neutrophil produced short cationic peptides, can inhibit the replication of
influenza virus [109]. Another important soluble factor is the complement system. The
complement is a heat labile, enzymatic mediator of the innate immune system that helps in
the clearance of pathogens by increasing the phagocytic clearance of the pathogens.
Complement present in human serum can neutralize influenza virus and in vivo
experiments found that in association with natural antibodies (IgM), complement can
provide protective immunity in influenza naïve hosts [110-112]. Furthermore, complement
deficient mice were more susceptible to influenza virus infection [113].
2.4.3. Cytokine and chemokine system
Cytokines are a diverse family of small proteins that are produced in response to
different stimuli for intracellular signaling and communicatios. They play an important role
during viral infections. Interferons are a type of cytokine that are produced during viral
infections and are aptly named because of their ability to interfere with viral replication.
While IFN-α and IFN-ß are type-I IFNs, IFN-γ is often called a type-II IFN. Although
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most nucleated cells can produce the type-I interferons, pDC are considered as the
specialized producers of these cytokines [114]. pDCs bind to a common cell surface
IFN receptors and activate transcription of hundreds of ISGs. Several protein products of
ISGs have anti-viral activities. For example, while OAS helps in degradation of viral RNA,
PKR has an inhibitory effect on viral protein synthesis. Another ISG protein, Mx is
associated with resistance against influenza infection [115]. On the other hand, IFN-γ is
primarily produced by T-cells and NK cells and its function is to activate macrophages.
Interleukins, produced by leukocytes, are mainly regulators of immune cell differentiation
and activation. A number of interleukins have been identified so far which can act locally
or systemically to exert divergent effects on both innate and adaptive immune
responses. Chemokines are the largest and fast growing family of cytokines that signal by
binding to one or more G-protein coupled receptors [116]. Depending upon the spacing of
their first two cysteine residues, chemokines are classified into four types (CXC, CC, C,
and CX3C). Chemokines function as chemoattractants to control the migration of cells,
particularly those of the immune system, and contribute to innate and adaptive immunity
[117]. Influenza virus infection induces the upregulation of several inflammatory cytokines
and chemokines such as IL-1β, IL-6, TNF-α, CCL-2 (MCP-1), CCL3 (MIP1-α), CCL3
(RANTES) and CXCL10 (IP-10)[118]. Current literature has conflicting reports on the role
of the cytokine and chemokine system during influenza infection. Some studies suggest
that influenza virus infection triggers a robust inflammatory cytokine response or “cytokine
storm” that is responsible for the pathogenesis of influenza while other studies identified a
protective role.
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2.4.4. Cells of innate immune system
Natural killer cells
Natural killer cells are a population of large granular lymphocytes with potent
cytotoxic activity and robust production of inflammatory cytokines such as IFN-γ, tumor
necrosis factor- alpha (TNF-α), and macrophage inflammatory protein-1 alpha (MIP-1α)
[119-121]. While, NK cells are broadly reactive against a wide variety of pathogens
including bacteria, virus, and intracellular parasites, their role during influenza is poorly
defined. Two NK cells receptors, natural cytotoxic receptors (NCR) Nkp46 (NCR- in the
mouse) and Nkp44, have been shown to recognize influenza virus HA on virus-infected
target cells [122, 123]. Moreover, large numbers of NK cells accumulate in the lungs of
infected host; and depletion or mutation of NK cell receptors resulted in increased
morbidity and mortality [124, 125]. Furthermore, adoptive transfer of donor cells, even at
<20% of the endogenous pulmonary NK cell content, resulted in restored protection [126].
Moreover, the differential activation of NK cells correlated with the pathogenicity of avian
influenza viruses [127]. NK cells have also been shown to enhance both DCs [128] and the
adaptive T-cell responses [129, 130] following influenza virus infection. Recently, it was
found that type-I IFN, but not IL-12 or IL-18, as critical for NK cell expression of both
IFN-γ and granzyme B in response to influenza infection [131].
Alveolar macrophage cells
Alveolar macrophages (AM) are one of the primary phagocytic and predominant
antigen presenting cells in the lungs. During homeostasis, AM are relatively quiescent and
have a regulatory cell phenotypes [132]. These homeostatic AM are less phagocytic and
produce relatively low amount of cytokines [132]. Interestingly, homeostatic AM have also
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been shown to suppress the induction of innate and adaptive immunity [133-136].
However, these homeostatic AM can be activated during influenza infection and convert
into highly phagocytic cells that produce robust amounts of inflammatory cytokines
including IL-6 and TNF-α [137]. Influenza infected macrophages also produce chemokines
such as RANTES, monocyte chemotactic protein-1 (MCP-1), and MIP-1α which further
recruit more mononuclear cells to the lungs to aid in viral clearance [138]. Besides their
contribution to viral clearance, especially in the case of seasonal influenza, AM have also
been implicated in influenza virus pathogenesis [139, 140]. Nevertheless highly pathogenic
IAV was found to induce significant recruitment of AM to the lungs [141, 142]. However,
studies using depletion of AM suggest that these cells are critical in the early protection
during influenza. Depletion of AM prior to, but not, 3 or 5 days following influenza
infection resulted in uncontrolled viral replication and a significant increase in mortality
[143]. Likewise, pigs depleted of AM prior to influenza infection exhibited increased
respiratory stress, reduction in lung TNF-α levels and increased IL-10. AM depletion also
reduced numbers of virus-specific CD8+ T-cells in the lungs and led to a diminished
antibody response [144]. Taken together, these observations suggest that AM may have
both protective as well as detrimental roles, due to excessive inflammatory cytokine
production- during influenza virus infection; and a balanced AM response is essential in
controlling the influenza virus infection.
Dendritic cells
Dendritic cells are a unique population of cells that play a pivotal role in molding
immune response against invading pathogens. DCs are one of the most potent antigen
presenting cells (APC) and play a pivotal role in bridging the innate and adaptive immune
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system following influenza virus infection. In the naïve homeostatic state, DCs are
distributed throughout the respiratory tract including airway epithelium, lung parenchyma
and the alveolar space of the lungs where they constantly survey for invading pathogens or
foreign materials. While lung resident DCs constitute a heterogeneous population in terms
of their surface phenotype and function, predominant DCs in the naïve lungs are airway
and alveolar DCs characterized by expression of CD11c+MHCII+CD11bneg CD4negCD8neg,
and interstitial DCs characterized as being CD11c+MHC II+CD11bhiCD4negCD8neg [145149]. Pulmonary insult or infection results in a significant influx of CD11c+MHCII+ DCs
in to the lungs increasing in the number of alveolar DCs and interstitial DC, as well as
recruitment of other subsets such as inflammatory monocyte derived DC (MoDC), pDC,
and CD8α+ DCs [139, 150-152]. While most influenza viruses can infect DC and lead to
viral protein synthesis, infection is generally abortive and does not produce progeny virus
[153, 154]. However, some highly pathogenic H5N1 viruses have been described to
replicate in human and mouse DCs and result in cytopathic effects [118, 155]. Following
infection by or encounter with IAV, DCs initiate production of proinflammatory cytokines
and chemokines that can include IL-6, IL-12, TNF-α, IL-8, IP-10, RANTES, MIP-1β, and
most importantly, type-1 IFN (IFN-α and IFN-β) [156]. Type-I IFN possesses potent
antiviral properties and is critical to the control of IAV infection. However, influenza virus
possesses mechanism to subvert this critical antiviral response by virtue of its NS1 protein,
and it will be discussed later in the current chapter.
2.5. Pathogenesis of influenza
Depending on the virus subtype and host, pathogenesis and outcome of influenza
virus infection is variable. In a natural reservoir host, such as wild waterfowls, influenza
21

virus replication is limited to the gastro-intestinal tract and does not cause clinical disease
[157]. In general, influenza virus infection is also mild and non-fatal in other avian species
such as domestic poultry, turkey, quail and pheasants. However, some H5 and H7 strains
are highly pathogenic in birds and responsible for large scale outbreaks in recent years
[158]. In mammals, including humans and equines, influenza virus causes a respiratory
disease that could range from mild to highly fatal in severity. Uncomplicated cases of
seasonal influenza in human are characterized by symptoms such as fever, headache, sore
throat, malaise, anorexia and coughing. The virus primarily infects and replicates in ciliated
columnar epithelial cells of the upper respiratory tract and subsequently infects cells of the
lower respiratory tract. Macroscopic pathogenesis of influenza involves physical damage
to respiratory epithelium, increased cellular infiltration and respiratory edema. The
molecular basis of the pathogenesis is mainly due to shut down of host cell protein
synthesis, apoptosis, inhibition of cellular anti-viral factors, and modulation of cellular
signaling molecules that results in altered cytokine/ chemokine response. Modulation of
respiratory cytokine and chemokine milieu by influenza virus also results in altered
recruitment of the effector cells of the respiratory innate and adaptive immune systems.
Influenza virus NS1 has a predominant role in the pathogenesis of the influenza virus and
will be discussed below. Secondary bacterial infection also plays a major role in the
pathogenesis and mortality associated with influenza and its role during influenza will be
reviewed later in the current chapter.
2.6. Role of NS1 in pathogenesis and immunity to influenza
Although the NS1 protein is not a structural component of the virion, it is expressed
at very high levels in the infected host cells and performs various functions critical for
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pathogenicity and replication of IAV. NS1 has been shown to inhibit critical steps of the
host innate as well as adaptive immune responses. NS1 has also been implicated as a critical
factor in several other viral functions including control of viral replication [159],
facilitation of viral mRNA translation [160], inhibition of host mRNA processing [161163], and regulation of apoptosis [164, 165].
2.6.1. Antagonism of cellular antiviral mechanism
One of the well-studied functions of the NS1 protein of the influenza viruses is to
inhibit host type-I IFN mediated antiviral defense. By using IAV with a truncated form of
NS1 or complete deletion of NS1 (delNS1) it was shown that NS1 is critical in
counteracting the host IFN response [166-168]. Whereas, delNS1 viruses replicated
efficiently in IFN-deficient systems such as vero cells, these viruses were highly attenuated
in an IFN-competent system [169]. The attenuated phenotype of these viruses might be due
to potent induction of the IFN-α/β in IFN-competent system [167]. Several groups have
investigated the mechanism of NS1 mediated inhibition of Type-I IFN, and it is now
evident that, depending on the strain, NS1 anti-IFN activity could either be at pretranscriptional or post-transcriptional level [170-172]. IFN antagonistic activity of NS1
protein of PR8 relies on blocking the dsRNA-and virus- mediated activation of key
regulators of IFN-β mRNA transcription such as interferon regulatory factor-3 (IRF-3),
NFκB and c-jun/ATF-2 that are essential for IFN-β mRNA synthesis [173-175]. Posttranscriptional inhibition of IFN-β by NS1 is mediated by its interaction with CPSF30 and
PABPII. Studies using IAV Udorn/72 (Ud) found that the C-terminal effector domain of
Ud-NS1 binds to two zinc finger domains of CPSF30 [176, 177] and interacts with PABPII
[57] resulting in inhibition of polyadenylation and nuclear export of cellular mRNAs.
23

OAS and the PKR are the two major cytoplasmic anti-viral proteins. Besides their key roles
in regulation of viral transcription and translation, both of these proteins have critical roles
in other innate defense mechanisms of the host such as IFN-β induction and apoptosis [178,
179]. Influenza virus NS1 has been shown to directly inhibit OAS [60] as well as PKR
[180]. A key event for the activation of OAS is binding of dsRNA, therefore RNA binding
activity of NS1 could lead to inhibition of OAS [181]. Since RNaseL of the OAS pathway
also participates in IFN-β induction [179], inhibition of OAS could also lead to suppression
of IFN-β [174, 182]. Binding of dsRNA releases the auto-inhibition of PKR and leads to
activation. Thus the dsRNA binding activity of NS1 was thought to result in competitive
inhibition of PKR [183, 184]. However, Li et al., observed that an NS1 protein defective
in dsRNA binding efficiently blocked the activation of PKR [185]. Moreover, NS1 was
also reported to interact with PKR through a dsRNA–independent mechanism that involved
critical role of residues 123-127 [180, 185]. Domain mapping studies suggest that NS1
binds to a linker region of PKR that prevents a conformational change otherwise required
to release autoinhibition [185]. Additionally, to counteract the effect of PKR, influenza
virus activates a latent chaperon related protein p58IPK that interferes with dimerization
and activation domain of PKR [186, 187], and has been shown to prevent apoptosis [188].
Activation of PKR leads to phosphorylation of cellular eIF2-α that results in reduction of
viral as well as cellular protein synthesis [178]. Inhibition of eIF2α is also critical in
regulation of ER stress-induced transcription factor CHOP-10 and induction of CHOP-10
is a key factor in deciding the fate of infected cell. While at early time points it helps to
restore the ER homeostasis, prolonged induction of CHOP-10 leads to apoptosis.
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2.6.2. NS1 and RNA interference (RNAi) pathway
Although the role of mammalian RNAi pathway in innate anti-viral defense is not
well established, NS1 has been suggested to antagonize putative RNAi-mediated innate
anti-viral mechanisms [189]. Whereas NS1 inhibited the host RNAi pathway in drosophila
and plant cell systems [190, 191], it has not been observed in the mammalian cells [192].
2.6.3. NS1 and apoptosis
Although the biological consequence of apoptosis during influenza virus infection
is yet to be defined, apoptosis is widely accepted as a cellular antiviral mechanism to limit
viral replication. While inhibition of apoptosis early during infection could promote events
such as viral replication, later during infection apoptosis may help in the efficient release
of progeny virus [193]. Influenza virus has been shown to possess anti-apoptotic activities
[165, 194-196]. Conversely, certain viral protein such as PB1-F2 and NA have been shown
to have pro-apoptotic activities [43]. The role of NS1 in apoptosis is controversial, and it
has been shown to have both pro-apoptotic [164, 197] as well as anti-apoptotic activities
[165, 196]. In MDCK cells, Zhirnov et al., observed that, as compared to the wild type PR8
virus, isogenic delNS1 virus induced higher level of apoptosis [165]. Although such
conflicting results may be due to differences in the experimental setup, there is an emerging
hypothesis that NS1 temporally regulates both early suppression and late induction of
apoptosis [51]. Activation of PKR during influenza virus infection has also been reported
to play a role in apoptosis [198]. Thus, direct binding and inhibition of PKR by NS1 could
also suppress apoptosis [51]. Likewise, suppression of the pro-apoptotic activity of
OAS/RNaseL [60] or the JNK/AP-1 stress pathway [173] could also contribute to antiapoptotic activity of NS1. Influenza virus activates the PI3K/Akt pathway by the binding
25

of NS1 to the p85 subunit of PI3K [199-201] and by viral RNA via RIG-I [202]. Activation
of the PI3/Akt pathway by NS1 limits the early induction of apoptosis [195, 200, 203].
2.6.4. NS1 and dendritic cell functions
Influenza virus NS1, in addition to its effect on innate antiviral defenses, also
interferes with critical components of the adaptive immune response. DC are the critical
sentinel cells of the adaptive immune system. Upon an encounter with foreign antigens,
DCs undergo maturation, release proinflammatory cytokines/chemokines and migrate to
lymph nodes where they present pathogen specific antigens to cytotoxic and helper T-cells
[193]. Presentation of antigens by dendritic cells activates cytotoxic T-cells that directly
kill the infected cells to eliminate the pathogen, whilst helper T-cells produce cytokines
such as IFN-γ and TNF-β that augment the cytotoxic activity of T-cells. NS1 protein of
influenza virus has been shown to reduce systemic and respiratory cytokines and prevent
TNF-α mediated depletion of bone marrow lymphocytes [204]. Influenza virus NS1 has
also been shown to interfere with the activation and maturation of DCs. Using a PR8 virus
mutant lacking NS1 and Newcastle disease viruses engineered to express NS1, FernandezSesma et al., found that NS1 inhibited expression of several genes crucial for the
maturation, migration and T-cell stimulatory activity of DCs [205]. Dendritic cells infected
with wild type PR8 virus failed to mature and did not induce secretion of IFN-γ from helper
T-cells. Additionally, NS1 affected only a specific set of genes that mechanistically appear
independent of IFN-β production. Important genes affected by NS1 included MIP-1β, IL12p35, IL-23p19, RANTES, IL-8, IFN-α/β, and CCR7 [205]. Monocytes are important
progenitor cells of DCs. Infection of equine peripheral blood monocytes with influenza
virus inhibited the differentiation of monocytes into DCs in response to GM-CSF and IL26

4 [153]. Despite a non-productive infection, infected monocytes displayed a morphology,
functional characteristics and cytokine profiles suggestive of arrested differentiation [153].
Reactivation of memory T-cells by bone marrow-derived DCs has been shown to be critical
in protection against influenza [206] therefore, prevention of DC maturation by NS1 has
important implications in viral clearance by the host.
2.7. Influenza and bacterial synergy
Although infection with some highly virulent influenza viruses alone can kill the
host, influenza-associated death may also be due to exacerbation of physiologic stress from
chronic health conditions or secondary bacterial infections. Among these, secondary
bacterial infections appear to be the most common cause of death due to influenza,
especially during pandemics [207]. Although Streptococcus pneumoniae (S. pneumoniae)
has been the most common bacteria, other bacteria such as S. aureus and H. influenzae
have also been linked to influenza-associated secondary bacterial pneumonia [207] [208].
The earliest associations between influenza and bacterial pathogens date back to the 17th
century when French physician Laennec observed increased cases of pneumonia following
an epidemic of influenza (“la grippe”) in 1803 [209]. In 1935 Andrewes et al. were first to
confirm secondary bacterial pneumonia following influenza infection where virus was
recovered from a patient who was febrile and then developed pneumococcal pneumonia
seven days into his convalescence and died [210]. The 20th century has seen at least three
well-defined influenza pandemics- “Spanish flu” (1918-19, H1N1), Asian flu (1957,
H2N2), and Hong Kong flu (1968-69, H3N2) resulting in 675,000 [211], 86,000 [212] and
56,300 [213] death, respectively, in the United States. The pandemic of 1918, which killed
about 40-50 million people worldwide [214], mostly due to secondary bacterial pneumonia
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[215-219], brought the focus on synergy between influenza and bacterial pneumonia. In
the following years, several epidemiological and laboratory studies were conducted that
supported secondary bacterial pneumonia as the major cause of death during influenza
infections. In the investigation of an epidemic in Boston during the winter of 1943-44,
Finland et al., [220] observed high titers of antibodies against IAV (PR8) from the cases of
bacterial pneumonia during and immediately following the epidemic and concomitant with
history of clinical influenza. They also isolated influenza virus from the lungs of three fatal
cases and concluded that the severity of the pneumonia was due to preceding influenza
infection [220]. In a study of an influenza epidemic in the Baltimore area during MarchApril of 1947, using virus isolation and serology, Maxwell et al. reported that 47% (17/36)
of cases of lobar pneumonia in humans were due to simultaneous infection with influenza
and pneumococcus [221]. Similar findings were reported by Tyrrell in an influenza
outbreak in Sheffield in 1949 [222]. In order to determine what killed the patients during
the 1918-1919 pandemic influenza, Morens et al., re-examined hematoxylin and eosinstained sections recut from the lung blocks obtained from 58 victims of the 1918 outbreak
available in the National Tissue Repository of the Armed Forces Institute of Pathology
[223]. The authors also reviewed 1539 pathology and bacteriology research records that
included 8398 individual autopsies from the 1918-1919 pandemic. From the
histopathological, epidemiological and microbiological data they suggested that a
synergistic association between influenza and bacterial pneumonia was responsible for the
unprecedented mortality seen during the 1918-1919 pandemic [224, 225]. Based on gross
pathology and bacterial isolation from blood only, 96% of 8000 cases reviewed showed
secondary bacterial infection [225]. Even with the widespread availability of antibiotics,
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more than two-thirds of fatal cases during the 1957 pandemic were associated with
bacterial pneumonia [207]. Recent epidemiological studies also suggest that influenza
infection predisposes the host to secondary bacterial infection. In a prospective study of
lower respiratory tract infection of 154 children, Michelow et al., observed that 23% of
children with identified pathogens showed influenza-associated secondary bacterial
pneumonia resulting in heightened lung inflammation and disease severity [226].
Similarly, in an epidemiological study using binomial regression, Grabowska et al.,
reported a yearly increase of 12-20% in invasive pneumococcal disease (IPD) per influenza
season, confirming a strong association between influenza and IPD [208]. The Center for
Disease Control (CDC) evaluated the lung tissue from 77 fatal cases from the 2009
pandemic influenza (H1N1) and observed that concurrent infection of bacterial pathogens
was evident in approximately one-third of the cases, approximately 50% of those cases
were due to S. pneumoniae [227].
Animal models for secondary bacterial infection following influenza were
attempted soon after the pandemic of 1918 [228]. In 1945, Mercedes and Torregrosa
developed a mouse model for secondary bacterial pneumonia [229]. Using the mouseadapted Influenza virus A / Puerto Rico/8/34 (PR8) and different strains of H. Influenzae,
S. Pneumoniae and S. aureus, they observed that preceding influenza infection resulted in
increased severity of bacterial pneumonia. Recently, McCullers et al., also developed a
similar mouse model to study the synergistic relationship between IAV and S. Pneumoniae.
They observed that influenza infection preceding the pneumococcal challenge increased
the severity of pneumonia and resulted in 100% mortality in mice. On the other hand,
pneumococcal infection preceding influenza infection resulted in protection from influenza
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and improved survival [230]. Although the relationship between influenza and
pneumococcus has been known for centuries [209], there are discrepancies that need to be
resolved. While laboratory animal experiments support synergy between pneumococcus
and influenza [231, 232] epidemiological data shows either limited association at best [233,
234] or no association [235]. Shreshta et al., developed a computer model that integrates
weekly incidence reports and a mechanistic transmission model within a likelihood-based
inference framework to define the nature, strength and temporal interaction between
influenza and pneumococcal pneumonia. Using their model, they analyzed weekly reports
of influenza and pneumococcal pneumonia from Illinois from 1989-2009 and observed that
influenza infection increased the susceptibility for pneumococcal pneumonia by
approximately 100 fold for a week following the initial influenza infection [236].
Mechanism of Synergy
Bacterial pneumonia during influenza could either be due to combined
viral/bacterial pneumonia or a secondary complication following influenza. Combined
viral/bacterial pneumonia has about a 10% mortality rate and is at least three times more
common than primary viral pneumonia [237]. Furthermore, differentiation of primary viral
or bacterial pneumonia is clinically challenging. Chest radiographs of patients with
advanced cases of viral pneumonia usually show bilateral interstitial infiltrate similar to
bacterial pneumonia [238]. Inflammatory markers also fail to distinguish between primary
viral and bacterial pneumonia. Secondary bacterial pneumonia with a mortality rate of
about 7%, on the other hand, is easily recognizable as it develops during the recovery phase
of influenza [239, 240]. Pathogenesis of influenza-associated bacterial pneumonia is
multifactorial and differs between concurrent bacterial infection and infection following
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influenza. It is important to note that concurrent viral/bacterial infection is relatively more
complex than post-influenza pneumonia. In combined viral/bacterial infection, both the
bacteria and the virus elicit a host defense response that could affect growth of both or the
other. On the other hand, pneumonia following influenza involves virus-induced changes
to the host and host response to bacteria [241, 242].
Physical changes in respiratory epithelium
Increased bacterial adherence to the damaged respiratory epithelium due to
influenza virus replication is the earliest explanation for increased susceptibility to bacterial
superinfection [243, 244]. Bacteriology and histopathology of lungs from the fatal cases of
hospital-acquired S. aureus pneumonia during 1957-58 influenza pandemic, showed
increased bacterial adherence in the areas of the bronchial tree where influenza virus
replication had denuded the epithelial layer [245]. Influenza virus infection can expose
basal membrane components such as fibrin that facilitate attachment of bacteria. In mice
infected with PR8 virus, and subsequently with S. pneumoniae, desquamation of tracheal
epithelium caused exposure of the basal cell layer and exposed basal membrane component
that favored the adherence of S. pneumoniae [246]. Additionally, influenza virus NA that
cleaves terminal sialic acid from cell surface glycoproteins could generate alternate
receptors, or virus-induced inflammation could activate some inactive cellular receptors
for bacteria [209, 230]. In a tracheal organ perfusion system, exogenous administration of
NA results in an increased number of receptors and adherence of S. pneumoniae [247].
Using a mouse model, McCullers and Bartmess found that influenza virus NA facilitates
bacterial adherence by stripping sialic acid from the lung, exposing receptors for
pneumococcus. Administration of selective NA inhibitor (Oseltamivir) improved survival
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and morbidity from influenza independent of viral replication [248]. Pairs of otherwise
isogenic influenza viruses generated by reverse genetics to express different N2 subtype
NAs showed a differential attachment of S. pneumoniae and development of pneumonia
proportional to the activity of expressed NA [249]. Besides NA, PB1-F2 of influenza has
also been implicated in the susceptibility to secondary bacterial pneumonia. Mice infected
with influenza viruses lacking PB1-F2 showed decreased susceptibility to secondary
infection [207]. Mice infected with a viral strain engineered to express PB1-F2 protein of
1918 pandemic influenza were more susceptible to pneumococcal pneumonia [250]. A
possible mechanism involves excessive lung damage and enhanced inflammatory
response; however, the exact underlying mechanism is unknown [207]. Upregulation of
cryptic cellular receptors might also contribute to increased bacterial susceptibility.
Influenza virus infection induces inflammatory cytokines that result in upregulated
expression of platelet activating factor receptor (PAFR) that can be used by pneumococci
for attachment [251]. The role of PAFR in bacterial superinfection, however, is
controversial. Influenza infected PAFR deficient mice infected with S. pneumoniae showed
significantly reduced bacterial outgrowth in the lungs, reduced dissemination of the
infection and prolonged survival [252]. However, antibody-mediated neutralization of
PAFR had no effect on secondary bacterial infection in influenza-infected mice [230].
Additionally, reduced clearance of bacteria from the influenza-infected lungs could also
predispose the host to increased bacterial burden. Influenza infection can result in
decreased function of surfactant protein and increased mucinous secretions that together
with fibrin and edema fluid and cellular infiltrate result in a dead space and ideal culture
conditions for bacteria [244, 253]. Impairment of the mucociliary escalator mechanism has
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also been observed during influenza [254, 255]. Substantial reduction in mucociliary
velocity was observed in influenza-infected tracheas as compared to the non-infected
tracheas [256]. Therefore, it appears that influenza infection results in decreased clearance
of bacteria leading to increased bacterial burden in the lungs.
Defective cellular innate defense
Although, defects in recruitment or activation of immune effector cells, such as
neutrophils, have also been implicated in enhanced bacterial superinfection during
influenza infection, their role is controversial. While most studies observed a reduced early
recruitment of neutrophils after subsequent bacterial challenge of influenza-infected mice,
some studies found that neutrophil recruitment 24 hrs post bacterial challenge is either
uninhibited or sometimes increased [242, 257-259]. Irrespective of levels of neutrophil
recruitment in the lungs, defects in the bactericidal functions of these cells such as
phagocytosis, respiratory burst, myeloperoxidase production and lysozyme production
have been detected [257, 260, 261]. Macrophage cells are strategic resident immune
effector cells in the lungs and act as immune sentinels for bacterial infections. Influenza
and other respiratory viruses have been shown to inhibit chemotaxis, phagocytosis and
microbicidal function of macrophage and monocytes. In the influenza infected individuals,
monocyte chemotaxis was suppressed 40%-72% during acute infection and reverted back
to normal by three weeks after recovery. Increased susceptibility to bacterial superinfection
in influenza patients can also be due to the virus-mediated suppression of monocyte
function [262]. In a mouse model, Kleinerman et al., found that, compared to the noninfected mice, influenza-infected mice showed 57% and 65% depression of total leukocyte
and macrophage accumulation, respectively. On the other hand, bacterial pneumonia did
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not suppress the macrophage response, suggesting that macrophage inhibition was
specifically due to influenza virus infection [263]. In dual infected mice, bacteria were
primarily bound to resident AM cells. Furthermore, depletion of alveolar macrophage cells
with liposomal Clodronate™ resulted in bacterial outgrowth in lung tissue as well as in
alveoli [264]. Defects in NK cell function has also been proposed to contribute to secondary
bacterial infections. In the mouse model, preceding influenza infection resulted in impaired
NK cell response to subsequent S. aureus infection. Adoptive transfer of naïve NK cells
restored the impaired host antibacterial response. This NK cell dependent impairment of
host antibacterial defense was due to reduced TNF-α production by NK cells that resulted
in depression of macrophage activation [265].
Dysregulated cytokine response
A fine balance of pro-inflammatory and anti-inflammatory cytokines is central in
determining the outcome of the immune response. A dysregulation of the cytokine and
chemokine balance during influenza has been observed and suggested to promote tissue
injury, as well as impair bacterial clearance. Increased production of pro-inflammatory
cytokines such as TNF-α, IL-6, IL-1β and chemokines, commonly referred to as a cytokine
storm, has been reported to contribute to the pathology of influenza infection of animals as
well as humans [257, 266]. Conversely, Shahngian et al., observed that influenza infection
resulted in decreased production of neutrophil activating chemokines such as MIP-2 and
keratinocyte-derived chemokine [KC] [259]. Imbalance in the release of anti- and proinflammatory cytokines could also suppress the effector response of innate immune cells.
Besides inflammatory cytokines, influenza virus also stimulates anti-inflammatory
cytokines such as IL-10 [266]. IL-10 limits both systemic as well as respiratory
34

inflammatory cytokine response of the host [267]. Additionally, enhanced release of IL-10
also results in suppression of leukocyte activity and impaired antibacterial response in the
lungs [268]. In a mouse model of post-influenza secondary pneumonia, Van der Slujis et
al., [242] observed that higher IL-10 levels, at least in part, were associated with increased
susceptibility to secondary infection with S. pneumoniae. Mice recovered from influenza
infection showed 50-fold higher expression of IL-10 in their lungs as compared to the lungs
of control mice. Furthermore, treatment with an IL-10 antibody before bacterial challenge
reduced the bacterial outgrowth and lethality of secondary pneumonia as compared to the
IgG1 control antibody treated mice [242]. However, studies with IL-10 knockout mice did
not show any improved outcome after dual infection [269]. Transforming growth factor-β
(TGF-β) is another important anti-inflammatory cytokine that has been implicated in
influenza-associated susceptibility to secondary bacterial infections. TGF-β is synthesized
as an inactive factor that needs to be cleaved to generate a biologically active form of TGFβ. Latent TGF-β remains linked with latency-associated peptide (LAP) attached noncovalently to the amino terminus of the immature TGF-β protein. Release of LAP from
TGF-β is essential for its binding to cellular receptors [270]. Influenza virus neuraminidase
is capable of processing the latent TGF-β to its active form in vitro resulting in increased
serum TGF- β activity as early as day one post-influenza infection [271]. Although
interferons including IFN-γ and type-I IFN (IFN-α and -β) are primarily believed to
participate in antiviral immunity, recent studies also support their role in suppressing
secondary bacterial infections. Sun and Metzger [231] reported that during influenza
infection, pulmonary T-cell produced IFN-γ inhibits bacterial phagocytosis by alveolar
macrophage cells and leads to increased susceptibility to secondary pneumococcal
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infection. Whereas exogenous administration of IFN-γ mimics the effect of influenza
infection and increases secondary bacterial susceptibility, neutralization of pulmonary
IFN-γ restores antibacterial immunity. Also, mice deficient in either IFN-γ or IFN-γ
receptor showed significant bacterial clearance as compared to wild type mice [264]. TypeI IFN such as IFN-α or IFN-β are soluble cytokines that act as the first line of defense
against viral infections and establishment of antiviral state and activation of various
immune cells [272] [273]. Influenza virus NS1 is a potent antagonist of IFN-α/β antiviral
responses [193]. Studies using influenza viruses engineered to express either truncated
forms of NS1 or lacking NS1 confirmed the role of this protein in counteracting host IFN
response [169, 274, 275]. Influenza viruses lacking NS1 (DelNS1) induce large amounts
of type-I IFN and are, therefore, highly attenuated in IFN-α/β competent system [193] and
display pathogenicity only in mice lacking antiviral signaling components such as STAT1 [276]. Influenza virus has also been shown to block IFN mediated anti-viral signaling.
Expression of H5N1 NS1 in HeLa cells suppresses IFN signaling in part due to NS1mediated inhibition of expression of the IFN receptor subunit [273]. Infection of ex-vivo
human non-tumor lung tissue with H5N1 and H1N1 viruses resulted in downregulation of
ifanr1 expression. Furthermore, infection of human monocyte-derived macrophages with
H5N1 and H1N1 viruses suppressed ifnar1 and ifnar2 expression [273]. Interestingly, IFN
receptor null mice (ifnr-/-) showed resistance to secondary infection with S. pneumoniae
when compared to wild type control mice [259]. Mice deficient in IFN receptor produced
significantly higher amounts of CXC chemokine resulting in greater recruitment of
neutrophils in the lungs [259]. Some studies suggest that the type-I interferon-mediated
suppression of TLR signaling through TRIF participates in regulating pro-inflammatory
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cytokines and chemokines [277]. However, the mechanism underlying the IFN mediated
suppression of chemokines is still poorly defined.
2.8. IL-23/IL-17 axis of innate immune response
IL-23 is a member of the IL-12 family of heterodimeric cytokines [278]. Functional
IL-23 is composed of a unique subunit-IL-23p19 and p40 subunit which is shared with IL12. Although IL-23p19 is expressed by a variety of tissues, it lacks any functional activity
by itself. Indeed, only activated macrophages and DCs secrete the biologically active IL23 heterodimer [279]. Since IL-23 also shares receptor IL12Rb1 with IL-12, it was
expected to have similar roles as IL-12 in promoting T helper 1 (Th1) type responses.
However, it has become evident now that IL-23 has different roles in regulating the
immune response. Importantly, IL-23 is a key factor in the development and maintenance
of a subpopulation of CD4+T cells called Th17 cells [280]. Based on the cytokine profiles
and functional properties, Mosmann et al., [281] proposed two classes of helper T (Th)
cells as Th1 and Th2 cells which participate in cell mediated immunity and humoral
immune response, respectively. After about two decades, an IL-23 dependent subset of
CD4+T cells, distinct from Th1 and Th2 cells, characterized by IL-17 secretion was
identified [282]. These Th17 cells do not express the T-bet or GATA3 lineage-specific
transcription factors of Th1 and Th2 cells, respectively [283, 284].
Initial studies found the IL-23/IL17 immune axis to be a major contributing factor
in the development of autoimmune diseases including experimental autoimmune
encephalomyelitis (EAE) [285], collagen–induced arthritis (CIA) and inflammatory bowel
disease (IBD) [reviewed by 286]. By studying the onset of EAE in IL-12p35, IL23p19 and
IL-12/23p40 knockout (KO) mice, Cua et al., reported that IL-12/23p40 KO mice were
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resistant but IL-12p35 KO mice were susceptible to EAE. They further observed that IL23p19 deficient mice were resistant to disease, indicating that IL-23 was important in the
development of EAE [287]. Likewise, it was found that IL-12p35 deficient mice were more
susceptible to CIA following immunization with type II collagen in complete Freund’s
adjuvant, whereas IL-23p19 or IL-12/23p40- deficient mice did not develop the disease
[288]. Recent evidence, however, also suggests a protective role of the IL-23/IL-17 axis in
the innate immune responses. Exposure of macrophages and DCs to lipopolysaccharides
(LPS) and other microbial products leads to the secretion of IL-23 from these cells [279,
289, 290], that induces a rapid release of IL-17 cytokines from Th17 cells [280, 291]. The
IL-17 cytokine family consist of six members (IL-17 A, B, C, D and F), however; only IL17A and IL-17F have been studied well and will be referred as IL-17 hereafter. Endothelial
cells and macrophage cells express IL-17 receptor and apparently are the main targets of
IL-17. IL-17 signaling in these cells results in induction of several pro-inflammatory
cytokines, including IL-6, IL-1β, IL-8 and TNF-α, which mediate host defense; as well as
several neutrophil chemoattractants such as CXCL-1, CXCL2, and CXCL5 that mediates
neutrophil recruitment to the infection site. Thus, the IL-23/IL17 immune axis might be an
important driving force in early immune responses against invading pathogens. IL-17 also
induces cytokines for targeting other immune cells to the mucosal surfaces. These include
CXCL9, CXCL10 and CXCL20 that possess chemotactic activity for lymphocytes and
DCs, and CCL2 and CCL7 that recruit monocytes. Additionally, IL-17 also induces some
antimicrobial peptides which can directly kill the pathogens [2]. Moreover, some of the
chemokines such as CCL20 also exhibit antimicrobial activity [292].

38

2.9. IL-23/IL-17 axis and immunity against pathogens
A protective role of the IL-23/IL-17 immune axis has been reported against many
bacterial and fungal pathogens [reviewed by 2]. IL-17 has been found to be critical for
recruitment of phagocytes that leads to the clearance of S. pneumoniae from the mucosal
surface of the nasopharynx [293]. Happel et al., found that IL23p19, IL-17 receptor (IL17R) and IL12p35 deficient mice were more susceptible to infection following
intrapulmonary inoculation with Klebsiella pneumoniae. They also observed that IL23p19
deficient mice had significantly lower IL-17A and IL-17F production in lungs, and despite
the normal IFN-γ levels in the lungs, these mice showed significant mortality from a
sublethal dose of bacteria (103 CFU). Notably, administration of recombinant IL-17
restored the protection against bacterial infection [294]. In a mouse model of streptococcus
lung infection, inhibition of the IL-23/IL-17 axis by morphine resulted in diminished
release of antimicrobial proteins S100A8/A9, reduced neutrophil recruitment and more
severe streptococcal infection in the lungs [295]. Markel et al., found that exogenous
administration of IL-17 or IL-23 had improved survival rates in pulmonary infection with
live vaccine strain (LVS) of Francisella tularensis, albeit to a limited extent. On the other
hand, antibody-mediated neutralization of IL-17 resulted in significantly higher mortality
(66.6%) as compared to the control mice infected with sublethal LVS [296].
Although the role of the IL-23/IL17 axis against bacterial pathogens has received
much attention, its role in viral infection is less explored, and there are conflicting findings.
The role of IL-12, IL-23 and IL-17 on viral host defense in poxvirus infection was
evaluated using vaccinia virus (VV) genetically engineered to express IL-12 (VV-IL-12),
IL-23 (VV-IL-23) or IL-17 (VV-IL-17) [297]. It was observed that VV-IL-23 and VV-IL39

17 were less virulent in BALB/c mice as compared with VV-IL-12 virus. Additionally, in
IFN-γ deficient mice infected with VV-IL-23 neutralization of IL-17 using anti-IL-17mAb
resulted in a significant increase in viral titers [297]. These findings suggested a protective
role of IL-23/IL-17 axis against VV. On the contrary, Patera et al., reported that VV-IL-17
was more virulent than the parental virus in mice, possibly due to altered generation of IgG
isotype antibodies [298]. Similarly, contrasting findings on the role of the IL-23/IL-17 axis
during influenza virus infection have also been reported. In mice infected with 100 PFU
IAV (PR8), IL-17A and IL-17F was induced as early as two days post-infection [299].
When mice deficient in IL-17R were challenged with PR8 virus, they showed less weight
loss and better survival rates than the wild type mice. Also, inflammation was less severe
in the IL-17 deficient mice as compared with wild type mice, possibly due to reduced
neutrophil infiltration and lower levels of IL-17 induced proinflammatory cytokines in IL17R deficient mice [299]. In contrast, when c57BL/6 mice challenged with 100 PFU of
influenza virus (PR8) for six days were subsequently challenged with 108 CFU of S.
aureus, clearance of both the bacteria and virus were attenuated. In addition, IL-17R and
IL-22 deficient mice had impaired bacterial clearance compared to the wild type mice.
Furthermore, exogenous supplementation of IL-23 via an adenovirus expressing IL-23
resulted in decreased lung inflammation, increased IL-17A and Th17 chemokines, and
increased clearance of bacteria and virus. Therefore, it appears that IL-23 overexpression
helps to restore the bacterial immunity and prevent increased susceptibility to secondary
bacterial infection [300]. These observations imply that the IL-23/IL-17 axis might have
a detrimental as well as protective effect during influenza virus infection. Therefore, to
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resolve this question, the relationship between the IL-23/IL-17 axis, influenza virus and
secondary bacterial infection needs further investigation.
2.10. Regulation of IL-23 expression
Although IL-23 has protective roles during the early innate immune response, its
chronic activation has been implicated in autoimmunity. Thus, a fine regulation of its
synthesis and secretion is necessary. IL-23 is a heterodimeric cytokine and formation of
biologically active IL-23 (p19/p40 heterodimer) requires synthesis of both the subunits
within the same cell. Therefore, regulation of IL-23 specific p19 subunit is critical in
determining secretion of biologically active IL-23. Transcriptional regulation of p40
(shared subunit) has been studied well, and it is now known that its expression is controlled
by various transcriptional factors such as NF-κB, C/EBP, ets-2, PU.1 and AP-1 [301-305].
However, owing to the recent discovery of p19, very little is known about the
transcriptional regulation of IL-23, or more specifically p19. Transcription factor NF-κB
was found to be critical for the expression of IL23p19 in dendritic cells [306] and
macrophages [307]. Liu et al. demonstrated that the ERK pathway was essential for IL23p19 gene expression. They also identified an Ap-1 element in the IL-23p19 promoter
and established that AP-1 was required for the IL-23p19 expression [308]. More recently,
Goodall et al. investigated the role of the endoplasmic reticulum (ER) stress pathway in
the expression of IL-23 in human dendritic cells. They found that ER stress-induced
transcription factor CHOP-10 was crucial for the IL-23 expression [309]. Their study
suggests that ER stress-induced by invading microorganisms could significantly affect the
IL-23-IL-17 mediated host innate immune response.
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2.11. Influenza virus and IL-23/IL-17 axis
The effect of influenza virus on IL-23 expression has not been investigated. In
human primary macrophages, Pirhonen et al., showed that, unlike Sendai virus, influenza
virus did not induce IL-23 [310]. Recently, Kudva et al., investigated inhibition of IL-23
by influenza virus. They found that when IFN-α receptor knockout (IFN-αR-/-) mice were
challenged by influenza virus and subsequently with S. aureus, preceding influenza virus
infection did not inhibit IL-23 or IL-22 production in IFN-αR deficient mice. Therefore,
they concluded that IAV induced type-IFN (IFN-β) is responsible for inhibition of the IL23 in lungs [300]. However, Fernandez-Sesma et al., observed that, as compared to the
dendritic cells infected with wild type virus, an NS1 deletion mutant influenza virus
(PR/8/34 DeltaNS1) induced significantly higher expression of both IFN-β, as well as IL23p19 [274]. Therefore, a different mechanism must exist for influenza virus mediated
inhibition of IL-23. Considering the role of ER stress-induced transcription factor CHOP10 on IL-23p19 expression, one such mechanism of influenza virus mediated suppression
of IL-23-IL-17 axis could be inhibition of CHOP-10.
2.12. Influenza virus and ER stress response
Protein overload in the ER activates a signaling cascade collectively called the
unfolded protein response (UPR), which tries to resolve increased protein load. IRE1,
PERK and ATF6 are the sensors of ER stress and initiate downstream signaling events to
reduce the protein overload and increase cell survival. Activated IRE1 has
endoribonuclease activity, and it performs alternative splicing of XBP-1 mRNA with a
frame-shift leading to a premature stop codon and production of the active XBP-1
transcription factor [311, 312]. Active XBP-1 then translocates to the nucleus and activates
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transcription of ER chaperon genes involved in ER protein folding. ATF6 is an ER resident
transmembrane protein which in the event of ER stress is cleaved by serine proteases in
Golgi apparatus and translocates to the nucleus where it activates transcription of UPR
target genes. PERK is an eIF2α kinase which helps in reducing ER overload by attenuating
protein synthesis through phosphorylation of eIF2α [313]. Phosphorylation of eIF2α,
however, results in preferential translation of ATF4 that activates downstream targets,
including CHOP-10. There are two possible outcomes of the UPR pathway activation either the cell resolves the protein overload issues and survives or if it fails to resolve the
protein overload apoptosis ensues. Levels of CHOP-10 have a crucial role in determining
the fate of the cells as its long-term induction results in apoptosis such as in the case of
prolonged ER stress in the cell.
The effect of influenza virus on ER stress has been the focus of several studies.
Indeed, it was found that IAV infection of primary tracheal epithelial cells of mice activated
ATF6 and increased ERp57, but not CHOP-10 [314]. ERp57 is known to be involved in
folding of hemagglutinin (HA) protein of influenza [315]; therefore, its upregulation might
be favorable for influenza virus replication. Viruses rely heavily on cellular machinery for
their replication. Therefore, unlike the induction of ERp57, induction of CHOP-10 might
be detrimental to the virus replication. Thus, it is intuitive to speculate that influenza
viruses might possess mechanisms to inhibit expression/activation of CHOP-10. Whether
influenza virus infection inhibits the expression of CHOP-10 in IL-23 secreting cells such
as macrophages is not known and needs to be investigated. NS1 is a multifunctional protein
of influenza virus that has been shown to interact with viral RNP complex [316] and is
important in viral replication and selective enhancement of viral mRNA translation [317,
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318]. Influenza NS1 protein has also been shown to inhibit the induction of important host
antiviral proteins- the type-I IFNs. Influenza virus NS1 protein, therefore, seems to be a
suitable candidate for the viral factor involved in the modulation of the ER stress response
pathway. Whether influenza virus infection inhibits the expression of CHOP-10 in IL-23
secreting cells such as macrophages is not known and needs to be investigated.
2.13. Equine influenza virus
Equine Influenza is a common respiratory viral disease of equids caused by IAV.
Based on the reactivity of the HA and NA surface proteins, equine influenza viruses (EIV)
have been divided into two subtypes, H7N7 and H3N8 respectively. Of the two EIV
subtypes, only the H3N8 subtype is currently in the circulation and responsible for
outbreaks of the disease and is endemic to the equine population in the United States and
most of the world [319]. The disease is highly contagious and after an incubation period of
1-3 days the clinical picture is characterized mainly by high fever, a serous nasal discharge,
dry, harsh nonproductive coughing and swelling of the submandibular lymph nodes [320].
Equine influenza itself is generally non-fatal except in donkeys [321] and mildly affected
animals recover within 2-3 weeks. However, in severely affected horses it may take up to
six months. Secondary bacterial infections such as Streptococcus zooepidemicus,
Pasteurella and Actinobacillus spp. [322] often complicate the disease. In cases of
secondary bacterial infections a second febrile response that is generally higher and of
longer duration, typically develops 2-3 days after initial fever. In such cases nasal discharge
becomes mucoid to mucopurulent; coughing and respiratory distress are more pronounced,
and if untreated could lead to severe bronchopneumonia that could be fatal. Exercise and
training need to be stopped as they could reduce the rate of recovery. Lost training and
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performance due to influenza, therefore, heavily influence the economy of the equine
industry. Secondary bacterial pneumonia may further delay the recovery and contribute
even more to the losses due to equine influenza. Significant improvements, since the
discovery of the virus, have been made in understanding the pathobiology of the virus and
development of vaccines. However, despite the regular use of vaccines, outbreaks of equine
influenza continue to occur [323, 324]. Thus, research on novel preventive and therapeutic
interventions is highly sought after.
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CHAPTER 3
Modulation of endoplasmic reticulum stress pathway by influenza virus
3.1. Introduction
Influenza A virus is the etiological agent of one of the most common respiratory
diseases of birds and mammals that results in seasonal epidemics as well as occasional
pandemics with significant mortality and economic losses. Each year, seasonal influenza
epidemics result in 3-5 million severe cases and 250,000-500,000 deaths worldwide. In
United States alone, influenza virus infection is estimated to result in 226,000
hospitalizations and 36,000 deaths [325, 326]. Antivirals such as neuraminidase inhibitors
and M2 ion channel inhibitors have been used in the past with limited success. Thus annual
vaccination is currently the most preferred method for control of influenza. Current
vaccines for seasonal influenza are based on predicting the vaccine strain on the basis of
surveillance data and carry an inherent risk of failure. Additionally, with current
technology it would be difficult to prepare large amounts of vaccines in a limited time.
Pathogenesis of influenza involves a complex interplay of host and viral factors. Despite
decades of research there are still unresolved areas in the interaction of host cells and
influenza virus. Further understanding of influenza virus and the host cell would be a
valuable resource in developing new therapeutic and preventive modalities. The current
study was designed to understand the interplay between influenza virus and the cellular ER
stress response of host.
The ER stress response, also known as unfolded protein response (UPR), is an
evolutionary conserved molecular cascade that helps to maintain ER homeostasis and
protein folding capacity during ER stress. However, recent advances in the field suggest a
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broader range of effects of ER stress response in multiple cellular and disease processes
such as apoptosis, inflammation, and metabolism [327-333]. In mammalian cells IRE1,
PERK and ATF6 are the sensors of ER stress that initiate downstream signaling events to
reduce the protein load on the ER and the ER chaperone immunoglobulin heavy-chain
binding protein (BiP) also known as glucose-regulated protein 78 (Grp78) acts as a master
controller [334-336]. Activated IRE1 has endoribonuclease activity, and it performs
alternative splicing of XBP-1 mRNA production of the active XBP-1 transcription factor
[311, 312]. Active XBP-1 then translocates to the nucleus and promotes transcription of
ER chaperone genes that are involved in ER protein folding. ATF6 is an ER resident
transmembrane protein which in the event of ER stress activates transcription of UPR target
genes including chaperone proteins. Activation of PERK leads to phosphorylation of eIF2α at serine 51 that leads to the inhibition of general protein synthesis to reduce the protein
overload in the ER [337].
Since viruses rely heavily on the host cell protein synthesis machinery, the
functional status of the ER may significantly affect viral replication and pathogenesis. For
example, influenza virus uses ER chaperone protein Erp57 for the folding and maturation
of HA protein [315]. Therefore, differential regulation of ER stress could be important in
the pathogenesis and replication of viruses [3]. Differential activation of ER stress response
pathways has been reported for multiple virus [3, 314, 338]. Although differential
regulation of the ER stress response by influenza virus has been shown in tracheal epithelial
cells [314, 338], ER stress response of macrophages, important in the pathogenesis as well
as control of influenza virus, has not been investigated. Moreover, viral factors involved in
the differential activation of ER stress response have not been investigated.
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CHOP-10, a key mediator of ER stress response, is a potent inducer of apoptotic cell death
[339]. Influenza virus lacking NS1 (delNS1), as compared to the wild type virus, has been
reported to induce significantly higher apoptosis. Therefore, the study was designed to test
the hypothesis that influenza virus NS1 protein is responsible for differential activation of
ER stress response and inhibits the expression of CHOP-10 in mouse macrophage. The
hypothesis was tested using recombinant influenza virus lacking NS1 (delNS1) otherwise
isogenic to PR8 virus, and Newcastle disease virus (NDV) engineered to express NS1
protein of PR8 virus. The results of study suggest that NS1, at least in part, mediates the
inhibition of CHOP-10.
3.2. Materials and methods
RAW264.7 Cells: RAW264.7 cells (RAW hereafter) were used as a surrogate for murine
AM. To make sure the observed results are not due to altered physiology due to culture
conditions RAW cells used in the study were obtained from two different sources (ATCC
and a kind gift from Dr. S. Straley at University of Kentucky). Cells were cultured in
growth medium (RAW-GM) (high glucose (4.5g/L) and low sodium bicarbonate (1.5
gm/L) containing DMEM- supplemented with 10% fetal bovine serum (Hyclone) and
penicillin-streptomycin solution (CellGrow) to give a final concentration of 100 I.U.
penicillin and 100 μg/mL. For the subculture, cells were gently scraped with a cell scraper
and resuspended in RAW-GM for seeding at appropriate density into the new culture
vessels. For in vitro infection experiments, after inoculation cells were cultured in high
glucose and low bicarbonate DMEM supplemented with 0.35% BSA and 1ug/mL trypsin
(Sigma) (RAW-SFM).
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For the mRNA expression studies, 1x106 cells were seeded in 12 well tissue culture
plates in duplicate/treatment and incubated overnight at 37○C/5% CO2. Before infection
cells were washed three times with pre-warmed phosphate buffered saline (PBS, pH 7.4)
and inoculated with virus as desired multiplicity of infection (MOI) in 200uL final volume
of inoculum. Virus was allowed to adsorb for 1hr at 37○C/5% CO2. After adsorption, cells
were washed three times in pre-warm PBS to remove unabsorbed virus. Cells were then
fed with pre-warmed RAW-SFM containing 1ug/mL trypsin and incubated for the desired
time at 37○C/5% CO2.
Viruses: Wild type and recombinant PR8 virus lacking NS1 gene (delNS1) generated by
reverse genetics (obtained from Dr. Peter Palese and has been described previously [276]).
This virus replicates efficiently only in substrate or hosts deficient in the type-1 IFNs (IFNα/β), therefore the viruses were grown in Vero cells that lack type-I interferon signaling.
Vero cells were cultured in DMEM containing 10% fetal bovine serum (Hyclone) and 1X
PSA solution (CellGrow) at 37○C/5% CO2. For virus isolation cell were seeded in roller
bottles and medium was supplemented with HEPES (CellGrow) at 20mM final
concentration. After inoculation with virus, cells were cultured in DMEM supplemented
with 0.35% bovine serum albumin (BSA), 1X PSA solution (CellGrow), HEPES at 20mM
and 1ug/mL trypsin (Sigma). After 48 hrs cell culture supernatant was collected and
clarified by centrifuging at 3000 RPM for 30 min at 4○C. Clarified virus was further
concentrated by pelleting at 26000g for 2hrs at 4○C over 25% sucrose cushion. After
centrifugation the supernatant was removed and pellet was resuspended in DMEM
supplemented with 5% glycerol and stored at -80○C in single use aliquots. Viral titer was
determined by performing TCID50 titer analysis in Vero cells.
49

Recombinant B1 vaccine strain of Newcastle disease virus expressing NS1 of PR8
virus (NDVB1-NS1) and parent virus (NDVB1) were a kind gift from Dr. Adolffo GarciaSastre (Mount Sinai, NY). Recombinant NDV viruses were generated by reverse genetics
as described previously [340]. Design of the NDV constructs is given in figure 3.1. The
viruses were grown in the 10 day old chicken embryos and allantoic fluid was harvested
48 hrs after inoculation. Allantoic fluid was clarified by centrifugation at 3000RPM for 30
min at 4○C. Virus was distributed as single use aliquots and stored at -80○C. EID50 titer
was determined following method the method of Reed and Meunch [341].
RNA extraction and Real-time PCR: Total cellular RNA was extracted using Purelink®
RNA mini kit (Life Technologies) with on column DNase digestion using Purelink®
DNase (Life Technologies). At the desired time point, media was removed from the wells
and cells were washed once with PBS. Cells were lysed in the wells with 600uL of RNA
lysis buffer supplied with the kit. Cell lysates were homogenized using shredder columns
(Qiagen) followed by RNA extraction protocol with on column DNase digestion supplied
with the Purelink® RNA mini kit (Life Technologies). Total cellular RNA concentration
and purity was determined by UV spectrophotometry using Nanodrop™ and a total of 1µg
total RNA was reverse transcribed using high capacity RNA-to-cDNA© kit (Life
Technologies) following protocol supplied by the manufacturer. Relative mRNA
expression of the markers of different ER stress pathways (Table 3.1) was analyzed by
quantitative real-time PCR using commercially available pre-validated Taqman© assays
(Applied Biosystems) and Taqman® Universal Master Mix II no UNG (2X) (Applied
Biosystems) following manufacturers recommendations. Briefly, 20 µL cDNA was diluted
to a final volume of 100 µL and a 4.5 µL cDNA was used in real-time PCR reaction with
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a final volume of 10uL with 1X final concentration of Taqman® assay and mastermix.
Each sample was run in duplicate on ABI 7900HT sequence detection system (Applied
Biosystems) following the standard protocol suggested by the assay manufacturer.
Amplification data was exported to LinregPCR [342] for the calculation of efficiency of
real-time PCR reactions. LinReg PCR efficiency calculations were based on the slope of
linear regression line containing 4-6 data points. For relative quantitation, only the
reactions with efficiency ranging between between 2± 0.2 (2 =100% efficiency) and R2
(squared correlation coefficient) greater than 0.98 were used for data analysis. Relative
expression was analyzed by the ΔΔCT method [343]. Murine GAPDH was used as an
internal control and mock infection was used as a calibrator for relative expression analysis.
Western blotting: For immunoblotting, 5x106 RAW264.7 cells were plated in a 60 mm
tissue culture dish and incubated overnight. Cells were infected with the respective viruses
at a MOI of 2 TCID50/cell as described above. Two sets of cells were mock inoculated.
While one of the mock inoculated cells served as negative control, the second one was
treated with 0.025uM Thapsigargin (TG, T-7459, Life Technologies) for 12 hrs and served
as positive control. At 20 hrs PI cells were washed twice with cold Ca++ and Mg++ free PBS
(pH 7.4) and cells were harvested by gentle scraping. Scraped cells were resuspended in
cold PBS and centrifuged at 600g/5min at 4οC. The Supernatant was carefully removed,
and cells were lysed by resuspending in 200 µL RIPA lysis buffer (Santacruz
biotechnology) supplemented with Halt protease and phosphatase inhibitor cocktail™
(ThermoScientific Pierce) at 1X final concentration following manufacturer’s
recommendation. Cells were kept on ice during lysis. Total cell lysates were clarified by
centrifuging at 16000g/5 min 4οC. Total cell protein obtained was transferred to 1.5 ml
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microcentrifuge tubes as single use aliquots. Protein concentration was determined using
the BCA protein assay kit© (Thermoscientific Pierce) using the microplate procedure
supplied with the kit. For immunoblotting, approximately 30 µg of whole cell protein was
diluted 1:5 in denaturing protein loading buffer supplemented with protease inhibitors and
boiled for 5 min at 95 οC, cooled and then loaded for electrophoretic separation. Proteins
were separated by electrophoresis on 12% polyacrylamide gels (Laemmli, 1970), and
subsequently transferred to nitrocellulose membranes by semi-dry electrophoretic transfer
in Tris-glycine buffer (pH 8.3). The membranes were blocked for 1hr with PBS containing
5% non-fat dry milk (NFDM), 5% normal goat serum (NGS), and 0.05% Tween 20,
followed by primary antibody (anti-Influenza NP (Fitzgerald, Concrod, MA) and antimurine CHOP-10 (Santacruz biotechnology)) incubation for overnight at 4 0C in PBS
containing 0.1% normal goat serum (Sigma) and 0.1% nonfat dry milk (Carnations,
Nestle). After multiple washes, the membranes were incubated with peroxidase-conjugated
anti-rabbit (IgG-HRPO) secondary antibody (Jackson Immunoresearch Labs, Inc.) for 1 hr.
The membranes were then washed and incubated with Supersignal substrate (Pierce,
Rockford, IL, USA) for chemiluminescence detection, and visualized with a FluorChem
8800 imaging system (Alpha Innotech, San Leandro, CA).
Immunofluorescence assay: Indirect double immunofluorescence staining was used to
localize CHOP-10 and the influenza virus NP protein. For the immunofluorescence assay,
1x106 cells were seeded into the 12-well tissue culture plates with coverslip inserts. Cells
were infected with either PR8 or delNS1 virus at MOI of 2 TCID50/cell. For a negative
control, cells were mock infected with medium alone and for a positive control of CHOP10, mock-infected cells were treated with 0.025uM TG during last 7 hrs of infection. At 20
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hrs PI, cells were rinsed twice with cold PBS and then fixed with 4% paraformaldehyde
for 10 min at room temperature. After washing once with cold PBS, cells were
permeabilized with 0.2% Triton X-100 (Sigma) in PBS for 10 min at room temperature.
Nonspecific antibody-binding sites were blocked by incubation of cells with 10% normal
goat serum (Sigma) in PBS for 1hr. Mouse monoclonal primary antibody against influenza
virus NP protein (Fitzgerald, Concord, MA) and polyclonal rabbit antibody against murine
CHOP-10 (SC-575, Santacruz Biotechnology) were diluted in blocking solution at 1:100
and 1:50 dilution, respectively and reacted with cells for 1hr at room temperature. After
washing three times for 5 min each wash, cells were incubated at room temperature for 30
min with FITC-conjugated goat anti-mouse IgG antibody (Pierce, Rockford, IL) and Texas
red conjugated goat anti-rabbit IgG antibody (1:400 dilution in blocking buffer). Cells were
washed three times with PBS, and then coverslips were carefully blotted to remove excess
liquid. A small drop of Vectashield H-1200 (Vector labs) anti-fade medium containing
DAPI was placed on the coverslips and coverslips were mounted on to clean glass slides.
Slides were examined using Zeiss Axioplan-2 fluorescence microscope and images were
captured with cytovision /Genus™ software application.
Statistical analysis: Statistical analysis of data was performed by one way ANOVA, and
means of treatment groups were compared using Fishers least significant difference test
using GraphPad (Prism6.0) software.
3.3. Results
NS1 inhibits expression of BiP/Grp78 (Hspa5): BiP/Grp78 has been suggested as the
master regulator of the ER stress pathway therefore effects of influenza virus
NS1expression on the induction of BiP were studied first. The hypothesis was that NS1
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inhibits the ER stress response. So we expected that virus lacking NS1 (delNS1 and
NDVB1) will induce a higher expression of BiP as compared to the respective parental
viruses. In order to determine the role of NS1 on BiP mRNA expression, RAW cells were
infected either with PR8 virus or delNS1 and either with NDVB1 virus or NDVB1-NS1
virus at MOI of 2TCID50/cell. Cells were incubated at 37 C/5% CO2 for 20 hrs after
infection. Two sets of cells were mock infected to serve as controls. TG is a competitive
inhibitor of Sarco/endoplasmic reticulum Ca++ [344] and a potent inducer of ER stress.
Thus, one set of mock-infected cells was treated with TG (0.025uM) for the last 7 hrs of
incubation to serve as a positive control, while mock-infected cells were used as a negative
control and calibrator for relative expression analysis. Results of BiP mRNA expression
are presented in Fig 3.2. Being a potent inducer of ER stress TG, as compared to all other
treatments, induced significantly higher expression of BiP mRNA(P<0.0001). While
relative expression of BiP mRNA in the delNS1 virus treated cells was significantly higher
than the PR8 virus (P<0.0097), it did not differ significantly from the mock-infected cells.
Relative expression was significantly lower in the PR8 virus infected cells (P= 0.0114) as
compared to the mock-infected cells, as well as TG treated cells. These results suggest that
virus infection resulted in the inhibition of ER stress, however it was more pronounced in
the wild type PR8 virus. When compared to the mock-infected cells, neither NDVB1 nor
NDVB1-NS1 showed any significant difference (P>0.05). However, relative expression of
BiP mRNA was significantly lower in the NDVB1-NS1 infected cells as compared to the
NDVB1 infected cells (P= 0.0312). Together these data suggest that influenza virus
NS1protein causes downregulation of BiP protein in the RAW264.7 cells.
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Effect of NS1 on IRE1 Pathway: The IRE1 mediated branch of ER stress response was
evaluated by determining the relative expression of total XBP1 (unspliced) mRNA
expression as well as by determining the relative expression spliced form of XBP1 mRNA
in cells treated as above. Results are presented in Fig 3.3. As compared to all other
treatments, TG treated treatment resulted in a significantly higher expression of total as
well as spliced XBP1 mRNA (P<0.0001). DelNS1 virus induced a significantly higher
expression of Total XBP1 mRNA as compared to the PR8 infected (P = 0.0056) or mock
infected cells (P =0.005), suggesting that NS1 does inhibit XBP1 mRNA expression.
However, neither PR8 nor mock cells showed a significant difference in the mRNA
expression of spliced XBP-1. Although statistically not significant (P= 0.0507), expression
of spliced XBP-1 mRNA was approximately two-fold higher in the cells infected with
delNS1 virus as compared to the PR8 virus infected cells. As compared to the mock-treated
cells, both NDVB1 and NDVB1-NS1 induced significantly higher expression of total XBP
(P=0.0031 and 0.0079, respectively). While NDVB1, as compared to the mock-treated
cells, showed significantly higher expression of spliced XBP1 mRNA (P=0.0344), there
was no significant difference in the expression of spliced XBP1 mRNA between NDVB1NS1 and mock-treated cells (P=0.1361). These results indicate that influenza virus NS1
inhibits the IRE1 pathway of ER stress response by inhibiting the endoribonuclease activity
of IRE1, as well as downstream mediator XBP-1.
Effect of NS1 on ATF6 pathway: Expression of chaperone genes such as ERDJ3, GRP94
and ERP72, at least partly, depend on ATF-6 for their full upregulation [345, 346].
Therefore, to investigate ATF6 activation, mRNA expression of chaperone genes was
analyzed. Results of this experiment are presented in fig 3.4. DelNS1 virus, as compared
55

to the PR8 virus, induced significantly higher expression of chaperone genes ERDJ3
(P=0.0029) and GRP94 (P=0.047). However, PR8 virus, as compared to delNS1 virus,
induced significantly higher expression of ERP72 (P<0.0029). While expression of ERDJ3
and GRP94, were lower in the PR8 virus infected cells (P=0.0003 and 0.0015,
respectively); expression of ERP72 mRNA was significantly higher (P<0.0003) in the PR8
infected cells as compared to the mock-infected cells. There was no significant difference
in the expression of chaperone genes between NDVB1 and NDVB1-NS1 viruses (P=
0.1447, 0.1079, 0.1447 for ERDJ3, GRP94 and ERP72, respectively). These data suggest
that influenza virus differentially regulate the expression of ATF-6 pathway that may
involve NS1 mediated as well as NS1 independent mechanisms.
Effect of NS1 on PERK pathway: Activation of the PERK pathway leads to selective
enhancement of CHOP-10 transcription; therefore to analyze the PERK pathway, mRNA
expression of CHOP-10 was examined in cells treated as above. Results are presented in
Fig 3.5. Cells treated with TG showed a significantly higher expression of CHOP-10
(P<0.0001), as compared to all other treatments including mock and virus infections. While
delNS1 virus, as compared to the PR8 virus, induced significantly higher expression of
CHOP-10 (P=0.456), there was no significant difference in the expression of CHOP-10
between NDVB1 and NDVB1-NS1 infected cells (P=0.1029). However, expression of
CHOP-10 was approximately two-fold lower in the NDVB1-NS1 infected cells, as
compared to the NDVB1 infected cells (mean relative expression 6.815 and 3.275,
respectively). DelNS1 infected cells showed approximately five-fold higher expression of
CHOP -10, as compared to the mock-infected cells (mean relative expression 4.93 and 1,
respectively). On the other hand, expression of CHOP-10 was approximately three-fold
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lower in the PR8 infected cells as compared to the mock-infected cells (mean relative
expression 0.3 and 1, respectively).
Differences in the CHOP-10 expression levels between PR8 and delNS1 virus
infected cells were also reflected on the protein levels. Western blotting was performed on
total cellular protein from the cells treated as above. Western blotting was performed using
anti-CHOP -10 antibody (SC-575, 1:250 dilution, Santacruz Biotechnology) and anti-actin
(1:1000 dilution, cell signaling technology) was used as loading control antibody. Results
are presented in Fig 3.6. In the TG treated cells as well as delNS1 infected with delNS1
virus, higher levels of CHOP-10 protein were detected. On the other hand, CHOP-10
protein was barely detectable in the PR8 virus or mock infected cells. During the ER stress
response, once activated CHOP-10 translocates to the nucleus where it activates
transcription of other genes that have CCAT elements. Therefore, translocation of CHOP10 was examined using double immunofluorescence using anti-CHOP-10 (SC-575) and
anti-influenza NP antibodies in the delNS1 virus and PR8 virus infected cells. Mock
infected cells were used as a negative control, and TG treated cells were used as a positive
control. IFA analysis revealed that there was no detectable level of CHOP-10 in PR8
infected cells (Fig 3.7). On the other hand, delNS1 infected cells did show expression of
CHOP-10 that was mainly localized in the nucleus. Taken together these data suggest that
influenza virus inhibits the activation of PERK pathway. Furthermore, inhibition of CHOP10, at least in part, is mediated by NS1.
3.4. Discussion
In the recent years, the ER stress response has emerged as a critical player in the
pathogenesis and replication of viral infections and several groups have reported a
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differential regulation of ER stress response pathway by viruses including influenza [3,
314, 338]. One of the earliest reports on ER stress linking to influenza showed that
overexpression of a mutated, misfolded form of influenza HA protein induces ER stress in
the simian cells [347]. Recently, differential activation of UPR pathways by influenza virus
infection was investigated in murine tracheal epithelial cells [314] and human
tracheobronchial epithelial cells [338]. Macrophage cells have been implicated in the
pathogenesis [299] as well as in protection [348] from influenza virus; hence activation of
ER stress pathway in these cells may play a critical role in the pathogenesis of influenza.
Therefore, the current study was designed to examine the ER stress pathway in influenza
virus infected macrophage cells. Furthermore, this study, to best of my knowledge, also
appears the first to examine the role of viral NS1 protein in the ER stress response pathway.
ER stress-induced transcription factor CHOP-10 has been shown to induce apoptosis as
well as regulate the expression of certain cytokines such as IL-23 [4] and thus may have
important implications in the replication, pathogenesis and immune response against
influenza. Therefore the focus of this study was CHOP-10.
Overall, it was found that in murine macrophage cell line RAW264.7, influenza
virus infection resulted in inhibition of the IRE1 as well as PERK pathway. We also
observed that PR8 virus resulted in slight activation of ATF6 pathway with the exception
of chaperone protein ERP72 that was significantly upregulated by PR8 virus. Preferential
activation of the ATF6 pathway was also observed in murine tracheal epithelial cells where
influenza infection resulted in activation of ATF6 and an increase in ERp57 but not CHOP10 [314]. However, in contrast to the present study, in HTBE cells, influenza virus
activated the IRE1 pathway with little or no concomitant activation of PERK or ATF-6
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pathway [338]. These differences might be explained by the differences between cell
systems and time points for ER stress analysis. Macrophage cells are potent APCs and
secretory cells thus these might be more adept at handling the protein overload as compared
to the epithelial cells; thus macrophages cells may be more resistant to ER stress.
Furthermore, Hassan et al., [338] studied the ER stress response at early time point (12 hrs)
but present study and study by Roberson et al., [314] analyzed the ER stress marker
expression at later time point (20 hrs or later).
Most of the ER chaperone proteins depend on induction of the ATF-6 pathway,
therefore it is conceivable that up-regulation of chaperones might be crucial for viral
replication by preventing severe ER stress and eventual cell death. ERp57, a member of
protein disulfide isomerase (PDI) family of protein, is critical in the folding of influenza
virus HA [315]. ERp72 is also a member of PDI family of proteins and closely related to
ERp57. Therefore, upregulation of ERP72 might help in viral protein folding. Inhibition of
the ER stress response was reported to be critical in influenza viral replication.
Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt, has been shown to
possess molecular chaperone properties, and to alleviate ER stress response in vitro as well
as in vivo [332]. Restoration of the ER stress response using treatment of cells with
TUDCA, prior to influenza virus infection of HTBE cells resulted in significantly lower
titers of influenza virus as compared to the TUDCA non-treated control cells. While viral
RNA replication was not affected, there was markedly reduced viral protein synthesis in
TUDCA treated cells as compared to the non-treated cells, suggesting that influenza virus
required an impaired ER stress response for efficient viral replication [338]. Differential
activation of ER stress pathways has also been reported in other viruses. While hepatitis C
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virus induces the ATF6 pathway but blocks the IRE1 pathway [349], hepatitis B virus
induces ATF6 and IRE1 but not PERK [350]. As African swine fever virus (ASFV) uses
ER as a site for the assembly and maturation it is expected to induce ER stress, however,
in ASFV-infected cells, it did not induce activation of PERK pathway [351]. Currently, the
only known mechanism of activation of PERK, ATF6, and IRE1 is their release from BiP.
The mechanism behind differential activation of the different arms of the UPR is unknown
[3].
Activation of PERK leads to the phosphorylation of eIF2α that results in host
protein shutdown to resolve the ER stress. Phosphorylation of eIF2α, however, results in
preferential translation of ATF4 that activates downstream targets, including CHOP-10.
Induction of CHOP-10 and the consequent apoptosis might play a critical role in the
development of viral cytopathic effects, viral spread and pathogenesis. For example, UPR
was associated with induction of apoptosis in virus infected cells in Japanese encephalitis
virus [352], bovine viral diarrhea virus [353], tula virus [354], severe acute respiratory
syndrome coronavirus (SARS-CoV) [355]), and West Nile virus [356]).
In the present study, we found that influenza virus, although induced ER-associated
chaperone, did not induce CHOP-10. Further analysis of delNS1 virus and PR8 virus
revealed that NS1 protein was involved in the inhibition of CHOP-10 expression and
activation. Similar to our finding, AFSV, an ER tropic virus that was expected to induce
CHOP-10, was found not to inhibit induction and activation of CHOP-10 [351]. Although,
induction CHOP-10 and consequent host cell death by apoptosis may help in viral
pathogenesis, it may also affect the viral replication. Therefore, viruses might have evolved
with the mechanism to regulate the induction of ER stress associated apoptosis to facilitate
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their replication. In support of our hypothesis, a recent study found that although influenza
virus-induced ATF6 pathway it did not induce CHOP-10 [314].
Comparison of expression of ER stress response markers in wild type and mutant
virus either lacking NS (PR8 vs. delNS1) or expressing NS1 (NDVB1 vs. NDVB1-NS1)
suggests that NS1, at least in part, plays some role in the differential activation of ER stress
pathway. Moreover, higher expression of ERP72 was present in the viruses that expressed
NS1 protein (PR8 and NDVB1-NS1) suggesting that the NS1 protein might participate in
differential upregulation of ERp72. Moreover, influenza virus lacking NS1 (delNS1) have
been reported to induce apoptosis earlier as compared to the wild type virus [195].
Therefore, it seems possible that influenza virus NS1 protein might be the viral factor
involved in the inhibition of CHOP-10. In conclusion, our results support the hypothesis
that influenza virus infection results in a differential activation of UPR pathway that, at
least in part, may be dependent on the NS1 protein of influenza virus.
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Table 3.1: List of Taqman® assays used in this study

Target

Other name

Taqman ®Assay ID

BiP

Hspa5

Mm00517690_g1

ERP72

Pdia4

Mm00437958_m1

ERdj3

Dnajb11

Mm00518196_m1

GRP94

Hsp90b1

Mm00441926_m1

XBP-1 (U)

XBP1 unspliced

Mm00457357_m1

XBP-1 (S)

XBP1 spliced

Mm03464496_m1

CHOP-10

DDIT3, Gadd153

Mm01135937_g1

GAPDH

GAPD

Mm99999915_g1
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Figure 3.1: Schematic representation of NDVB1 and NDVB1-NS1 constructs
Adapted from: Park M et al. J. Virol. 2003; 77: 9522-9532
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Figure 3.2: Effect of influenza virus on BiP/GRp78 mRNA expression
Data are presented as mean ± SD and are representative of at least two independent
experiments carried out in duplicate.
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Relative expression
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Figure 3.3: Effect of influenza virus on XBP1 mRNA expression
Data are presented as mean ± SD and are representative of at least two independent
experiments carried out in duplicate.
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Figure 3.4: Effect of influenza virus on ATF6 pathway
Data are presented as mean ± SD and are representative of at least two independent experiments carried out
in duplicate.
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Figure 3.5: Effect of influenza virus on expression of CHOP-10 mRNA
Data are presented as mean ± SD and are representative of at least two independent
experiments carried out in duplicate.

30
20
10

Treatment

M
oc
k

TG
/L
PS

VN

S1

1
N
D

VB
N
D

PR
8

N
S1

0

de
l

67

Relative expression

40

Mock

Positive

NDVB1-NS1

NDVB1

PR8

delNS1

MW Marker

Figure 3.6: Effect of influenza virus on expression of CHOP-10 protein
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Actin (47 kDa)
CHOP-10 (34 kDa)

Figure 3.7: Effect of influenza virus on activation of CHOP-10
Nucleus is stained with DAPI (Blue), Influenza virus nucleoprotein detected with FITC
conjugated secondary antibody (green) and CHOP-10 detected with Texas red conjugated
secondary antibody. 100X magnification.
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CHAPTER 4
Influenza A virus NS1-mediated inhibition of CHOP-10 downregulates IL-23
4.1. Introduction
Influenza virus is a negative-sense single-stranded RNA genome-carrying virus
that causes one of the major respiratory diseases worldwide. Recent epidemiological and
laboratory studies provide a strong evidence that secondary bacterial pneumonia is the
major cause of death during influenza [209]. With emerging drug-resistant strains of both
influenza virus and bacteria, along with the looming threat of pandemic influenza, alternate
therapeutic measures become important. Pathogenesis of influenza virus depends on
intricate interaction of viral and host cellular factors, and the host innate immune responses.
Thus understanding these interactions would be important in identifying new therapeutic
targets.
IL-23 is a recently identified member of IL-12 family of heterodimeric cytokines
that is essential for proliferation of IL-17 producing Th17 cells. IL-17 has been shown to
induce other cytokines that help recruit other critical cells such as macrophage, monocytes
and neutrophils. IL-23/IL-17 mediated immune responses have been implicated in control
of a variety of respiratory bacteria [279], however, its role during influenza virus infection,
especially in the setting of bacterial co-infection, has just begun to be appreciated. In a
recent study, Kudva et al., reported that influenza virus-induced type-I IFN resulted in
inhibition of IL-23/IL-17 that caused increased susceptibility of the host to secondary
bacterial infection [300]. However, influenza virus is known to inhibit type-I IFN response.
Thus, there is a possibility that another mechanism might be involved in the influenza virus
mediated inhibition of IL-23.
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Multiple cellular transcription factors have been proposed to control the regulation
of IL-23, including CHOP-10 [4]. In previous experiments (Chapter III) influenza virus
was found not to induce the expression of CHOP-10. Therefore, considering these factors,
it was hypothesized that influenza virus NS1 mediated CHOP-10 inhibition results in the
downregulation of IL-23/IL17 pathway. In order to test this hypothesis, expression of IL23 was studied in vitro in murine macrophages as well as in vivo in a influenza mouse
model.
4.2. Materials and methods
Cells: Vero cells and RAW264.7 cells were cultured as described in the previous chapter.
Mouse primary alveolar macrophage cells (AM) were isolated and purified by a method
described previously [357] with minor modifications. Briefly, 6-8 week old female
c57BL/6 mouse (Harlan) was euthanized by intraperitoneal injection of 200 µL
Buthanasia-D™. Mouse was then sprayed with 70% ethanol, and the abdominal cavity was
carefully opened to bleed the mouse by severing abdominal aorta. Trachea was exposed
aseptically, and a small puncture was made with a sterile needle to insert a sterile catheter
made in-house using 20G Tygon® tubing. Catheter was attached to a three-way valve
connected to two 5cc syringes. One ml warm PBS (37○C) was infused through the trachea
with one syringe then the inlet valve was closed. The outlet valve was then opened and
while gently massaging the thoracic cavity fluid was aspirated into the second syringe.
After this, the valve was switched to the inlet syringe, and the process was repeated for a
total of 5 mL PBS. The BAL fluid thus obtained from several mice was pooled and
centrifuged at 400g/10 min at 4○C to pellet the cells. If BAL cells were contaminated with
red blood cells (RBC), the cell pellet was resuspended in 1ml ACK lysing buffer (Gibco)
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for 30 sec to lyse the RBC then washed again with PBS. The Cell pellet was resuspended
in RPMI-1640 (Invitrogen) medium supplemented with 10% FBS and 1X PSA solution
(AM-growth medium). Cell concentration was determined using a hemacytometer and
adjusted to 1x106/mL in AM-growth medium. In order to obtain pure population of alveolar
macrophages, BAL cells were plated in 100 mm tissue culture dishes and incubated at
37○C/5% CO2 for two-four hours with gentle rocking at every hour. After incubation, the
plate was gently rocked and tilted to collect aspirate medium containing unattached
lymphocytes and other cells. Attached cells are then washed once with growth medium and
then scraped, counted and seeded into desired culture vessels as per requirement of the
experiment. After adherence step, the cells are usually in ≥90% pure population of
macrophage and this method usually yields approximately 3-5x105 AM cells /mouse [357].
Infectious agents: PR/8/34 strain (PR8) of IAV and an isogenic recombinant virus lacking
NS1 (delNS1) as described in the previous chapter (chapter III) were used in the current
study.
For the bacterial infection, Streptococcus zooepidemicus (S. ze) strain 7e was used
(kind gift from Dr. John Timoney at Gluck Equine Research Center). The bacteria was
isolated from a clinical case of bronchopneumonia in donkey. One day before mouse
inoculation, bacteria were freshly streaked on Columbia CNA (Sigma) blood agar
containing 5% horse blood and incubated for 24 hrs at 37○C/5% CO2. A single isolated
colony was inoculated in 4 mL Todd-Hewitt broth for 6 hrs to achieve log growth phase.
After 6 hrs, bacterial culture was pelleted at 6000g/4οC for 20 minutes and then washed
twice with normal saline. Bacterial pellet was resuspended to 1x108 CFU/mL in normal
saline. Bacterial concentration was confirmed retrospectively in the inoculum by plating
72

serial dilutions on Columbia CNA (Sigma) blood agar containing 5% horse blood, and
colonies were counted at 24 hrs after incubation and results were presented as colony
forming units per mL (CFU/mL).
Infection of cells with the virus: For the mRNA expression studies in RAW264.7 cells,
cells were cultured and infected as described in the previous chapter. For mRNA
expression studies in the primary murine alveolar macrophage, 0.5x106 purified cells were
seeded in 24 well tissue culture plate and allowed to rest overnight. For infection, cells
were washed three times with pre-warmed PBS and inoculated with virus at 2 MOI in
100uL final volume of inoculum prepared in serum free RPMI-1640 (Gibco) supplemented
with 0.35% BSA (Lampire Biologicals), 1x PSA (CellGrow) and 1ug/mL trypsin (Sigma).
Virus was allowed to adsorb for 1hr at 37○C/5% CO2. After adsorption, cells were washed
three times in pre-warm PBS to remove unabsorbed virus. Cells were then fed with prewarmed serum free RPMI-1640 supplemented with 0.35% BSA (Lampire Biologicals), 1x
PSA (CellGrow) and 1ug/mL trypsin (Sigma). Cells were transferred to the incubator and
incubated for 20hr at 37○C/5% CO2.
RNA extraction and Real-time PCR: Total cellular RNA, cDNA synthesis and real-time
PCR using predesigned validated Taqman® assays (see Table 4.1) and relative expression
analysis was carried out at described in chapter III.
Stable expression of CHOP-10: An expression plasmid containing murine CHOP-10
cDNA under CMV promoter and neomycin resistance as a eukaryotic selection marker was
purchased from Origene (pCMV-Kan/neo) and used to generate RAW264.7 cells stably
expressing murine CHOP-10. RAW264.7 cells were transfected using Targafect-RAW
transfection reagent system (Targeting systems) following protocol supplied with the kit.
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For the selection of stable clones, 24 hrs after transfection, cell culture medium was
replaced with growth medium containing 0.6 mg/mL neomycin (G-418, Sigma) and
continued to be grown with replacing fresh selection medium every two days until
individual clumps of cells appeared. Individual clumps of the cells were then lifted with
cell scraper and transferred to separate cell culture dishes and cultured and passaged in
selection media. Stable clones were screened for expression of CHOP-10 using a Taqman®
assay as described earlier in this chapter. Stable clones of empty vector were prepared as
described above and were used as a negative control.
Lentivirus mediated knockdown of CHOP-10: Commercially available pre-validated
lentiviral particles for CHOP-10 shRNA and control shRNA were purchased from Sigma.
Lentiviral transduction was performed following manufacturer’s protocol. Briefly, the day
before transduction cells were seeded to achieve about 70% confluency on the day of
transduction. Immediately before transduction the cell culture medium was replaced with
growth medium containing hexadimethrine bromide (Sigma) at a final concentration of 8
µg/mL followed by addition of lentiviral particles to achieve MOI of five. Cell culture
medium was replaced at 24 hrs after transduction and followed by adding selection media
containing 0.5ug/mL puromycin on the next day. Fresh selection medium was added every
two days until individual clones of stable cells appeared. Individual clones of the cells were
then carefully lifted and transferred to the new culture dishes and cultured in selection
medium until ready for passage. Selection was continued for at least two weeks before
screening the clones for efficiency of knockdown which was analyzed by real-time PCR
using Taqman® assay as described earlier in this chapter.
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Animals: Six-eight week old female c57BL/6 mice were purchased from a commercial
supplier (Harlan). On arrival, mice were housed in microisolater cages with ad libitum
supply of food and water. Mice were acclimatized for one week before infection and
examined daily for any signs of stress or illness following the guidelines of Institutional
Animal Care and Use Committee (IACUC) at University of Kentucky. All the animal work
was approved by IACUC at University of Kentucky.
Inoculation of mice: Mice were sedated with ketamine/xylazine administered
intraperitoneally. Once sedated mice were held upright by holding from the loose scruff at
the neck. A small drop of inoculum was placed near each nostril so that mice involuntarily
inhaled the inoculum. Inoculum was instilled from alternating the nostrils so that whole
inoculum (60uL) was divided between two nostrils. After inoculation mice were
transferred back to the microisolater cages with ad libitum supply of fresh food and water
and observed for recovery. Mice were divided into six independent experimental groups
with six mice in each group. Experimentally treated groups were housed separately as three
mice/cage. Details of experimental groups are as following:
•

Control: intranasally inoculated with 60µL normal saline

•

delNS1: intranasally inoculated with 1000 TCID50 units of delNS1 virus in 60µL
normal saline

•

PR8: intranasally inoculated with 1000 TCID50 units of PR8 virus in 60µL of
normal saline

•

Zoo: intranasally inoculated with approximately 1x106CFU of S. zooepidemicus
(strain 7e) in 60µL of normal saline
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•

Zoo+delNS1: intranasally inoculated with 1000TCID50 units of delNS1 virus+
approximately 1x106 CFU of S. zooepidemicus (strain 7e) in combined volume of
60µL of normal saline

•

Zoo+PR8: inoculated with 1000TCID50 units of PR8 virus+ approximately 1x106
CFU of S. zooepidemicus (strain 7e) in combined volume of 60µL of normal saline

Bronchoalveolar lavage (BAL) fluid collection: At 12 hrs post infection mice were
euthanized by intraperitoneal injection of 200µL ButhanasiaD™, and BAL fluid was
collected aseptically using a sterile intra-tracheal catheter. A total of one mL sterile normal
saline was instilled in the lungs and aspirated. The aspirated fluid was re-infused and
aspirated for a total of three times. BAL fluid was centrifuged at 600g/5min, and cell-free
BAL fluid was transferred to sterile microcentrifuge tube as single use aliquots and frozen
at -80○C.
Data Analysis: Results in the RAW cells are presented as mean ±SEM and are
representative of at least three independent experiments. Results of primary alveolar
macrophage cells are from a single experiment done in duplicate. Data was analyzed by
using Prism6 (GraphPad Software).
4.3. Results
Effect of influenza virus NS1 on type-I IFN expression: Recently, induction of type-I
IFN was implicated in the influenza virus mediated inhibition of IL-23. However, influenza
virus NS1 is known to inhibit the type-I IFN response [172].Thus, before testing my
primary hypothesis, effect of NS1 on relative mRNA expression of IFN-β was tested in the
RAW cells as well as in primary alveolar macrophages. Cells were infected either with
PR8 virus or delNS1 virus at MOI of 2TCID50/cell and incubated at 37 C/5% CO2 for 20
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hrs after infection. Two sets of cells were mock infected to serve as controls. One set of
mock-infected cells was treated with TG (0.025uM) and LPS (100ng/mL, Sigma) for last
7 hrs of incubation to serve as a positive control while mock-infected cells were used as
negative control and calibrator for relative expression analysis. Murine GAPDH was used
as internal control for relative expression. Results are presented in Fig 4.1. In RAW cell,
delNS1 virus, as compared to the PR8 virus induced significantly higher expression of
IFN- β (P<0.0477). Similarly, in primary AM cells, expression of IFN-β was approximately
10 fold higher in the delNS1 virus-infected cells as compared to the PR8 virus-infected
cells. These results indicate that influenza virus NS1 inhibited the expression of type-I IFN,
as expected.
Effect of influenza virus NS1 on IL-23p19: IL-23 is a heterodimeric cytokine composed
of a p40 subunit that is shared with IL-12 and an IL-23p19 subunit that is unique to IL-23
[279]. Thus, in order to determine the effect of NS1 on IL-23, we analyzed the relative
expression of IL23p19 in the RAW cells and primary AM cells using total cellular RNA
from the experiment described above. The underlying hypothesis was that influenza virus
NS1 inhibits the expression of IL-23p19. Results of relative mRNA expression are
presented in fig 4.2. Results in the RAW cells are presented as mean ±SEM and are
representative of at least three independent experiments performed in duplicate. Results of
primary alveolar macrophage cells are from a single experiment done in duplicate.
Expression of IL-23p19mRNA, in the RAW cells, was significantly higher in the delNS1
virus-infected cells as compared to the PR8 virus infected cells (P<0.0446). Also, delNS1
virus infected AM showed higher relative expression of IL-23p19 as compared to the PR8

77

virus infected cells. These results suggest that influenza virus NS1 inhibits the expression
of IL-23.
Effect of Influenza virus NS1 on expression of CHOP-10: CHOP-10 is an ER stressinduced factor that, in human dendritic cells, has been shown to be critical in the expression
of IL-23. The hypothesis for this experiment was that Influenza virus NS1 protein inhibits
the expression of CHOP-10. In order to test this hypothesis, expression of CHOP-10 was
analyzed in primary AM of mouse and RAW cells were used for the purpose of
comparison. Relative expression of CHOP-10 was compared between delNS1 virus and
PR8 virus infected cells and results are presented in Fig 4.3. Results from the RAW cells
are presented as mean ±SEM and are representative of at least three independent
experiments performed in duplicate. Results of primary alveolar macrophage cells are from
a single experiment done in duplicate. As expected, RAW cells infected with delNS1 virus
infected cells showed significantly higher expression of CHOP-10 mRNA, as compared to
the PR8 virus infected cells (P<0.0286). Also, in the AM cells infected with the delNS1
virus CHOP-10 expression was approximately eight fold higher than the PR8 virusinfected cells. These results suggest that influenza virus NS1 inhibits the expression of
CHOP-10.
Effect of CHOP-10 overexpression on IL-23p19 expression: The hypothesis for this
experiment was that CHOP-10 overexpression will rescue the inhibition of IL-23 in PR8
virus infected cells. To test this CHOP-10 was overexpressed in the RAW cells and cells
were then infected with PR8 virus and expression of IL-23p19 was analyzed. Results of
this experiment are presented in Fig 4.4. Overexpression of CHOP-10 was confirmed by
real-time PCR. Expression of CHOP-10 was significantly higher in the expression vector
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(pCHOP-10) transfected cells as compared to the empty vector (pCMV) transfected cells
(p<0.0001). Although lower than the mock-infected cells, expression of CHOP-10 was
significantly higher (P=0.0027) in the PR8 virus infected cells transfected with
overexpression vector (pCHOP-10+PR8) as compared to the cells transfected with empty
vector (pCMV+PR8), suggesting that expression of CHOP-10 in the PR8 infected cells
was restored, at least partially. IL-23p19 mRNA expression was highest in the mockinfected CHOP-10 overexpressing cells (pCHOP10+Mock). Also, expression of IL23p19
mRNA was significantly higher (P<0.0001) in the PR8 infected cells overexpressing
CHOP-10 (pCHOP-10+PR8) as compared to the PR8 infected cells transfected with empty
vector (pCMV+PR8). These results suggest that restoration of CHOP-10 by plasmidmediated overexpression overcomes the influenza virus mediated inhibition of IL-23p19.
Effect of CHOP-10 knockdown on IL-23: In previous experiments, it was observed that
delNS1 virus infection of RAW cells and AM led to the induction of CHOP-10 and IL23p19 mRNA. Hence, this part of study was designed to investigate whether CHOP-10
inhibits the induction of IL-23p19 in the delNS1 virus infected cells. To test this, CHOP10 was knocked down in the RAW cells by lentiviral-mediated delivery of CHOP-10
siRNA. Cells were then infected with delNS1 virus and relative expression of CHOP-10,
and IL-23p19 mRNA was analyzed. Results in the Fig 4.5A confirm the siRNA mediated
knockdown of CHOP-10. As expected, cells transduced with CHOP-10 siRNA lentivirus
resulted in significantly lower expression of IL-23p19 as compared to control siRNA
transduced cells after infection with delNS1 virus (P=0.0019). These results suggest that
delNS1 virus-induced expression of IL-23p19 is mediated by CHOP-10.
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Effect of influenza virus NS1 on IL-23/IL-17 pathway in vivo: The delNS1 virus
infected cell induced significantly higher expression of both IFN-β and IL-23p19 in vitro
suggesting that IL-23 expression is not inhibited by type-I IFN. Therefore, it was
hypothesized that the influenza virus infection will inhibit the IL-23 pathway in vivo by a
mechanism that does is not mediated by type-I IFN. It was also, hypothesized that this
inhibition will result in downregulation of IL-17 that is secreted by Th17 cells. In order to
test these hypotheses, respiratory IL-23 and IL-17 induction was determined by analyzing
the expression of IL23p19 and IL-17A mRNA in the BAL cells of mice from different
treatment groups as described in the materials and methods section of this chapter.
Expression of IL23p19 was highest in the mice co-infected with S. ze and delNS1 and it
differed significantly from the mice co-infected S. ze and PR8 virus (Fig 4.6, P<0.0001).
Likewise, IL-17A expression was also highest in the S. ze and delNS1 virus-infected mice,
and it was significantly different as compared to the S. ze and PR8 virus co-infected group
(Fig 4.7, P<0.0001). However, contrary to in vitro results, there was no significant
difference in the expression of IFN-β between the S. ze and delNS1 virus co-infected group
and S. ze and PR8 virus infected groups (Fig 4.8). Moreover, induction of IFN-β was
minimal in all the treatment groups, and it was lowest in the delNS1 virus alone-infected
group.
4.4. Discussion
The IL-23/IL-17 pathway has been shown to play a critical role in the clearance of
secondary bacterial infection during influenza. However, viral and host factors involved in
the modulation of the IL23/IL-17 pathway during influenza are poorly understood. In a
recent study Kudva et al., suggested that influenza virus mediated induction of type-I IFN,
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especially IFN-β, is responsible for the downregulation of IL-23/IL-17 pathway [300].
However, influenza viruses are known to suppress type-I interferons in infected cells.
Therefore, presence of an interferon independent mechanism to downregulate the IL-23/IL17 pathway was speculated. CHOP-10, an ER stress-induced transcription factor, was
found to be critical in the regulation of IL-23 [4], and current study suggested that NS1
inhibits the expression of CHOP-10 (Chapter III). Thus, it was hypothesized that influenza
virus NS1 protein-mediated inhibition of an ER stress-induced transcription factor CHOP10 causes downregulation of IL23/IL17 pathway. The hypothesis was tested in vitro using
murine macrophage cell line (RAW cells) as well as in murine primary AM cells and
subsequently confirmed in vivo using a mouse model.
Relative mRNA expression of IFN-β, IL-23p19 and CHOP-10 in the delNS1 virusinfected and PR8 virus-infected RAW cells as well as in primary macrophages was
analyzed. As expected, in both cell types delNS1 virus resulted in significantly higher
expression of IFN-β suggesting that influenza virus NS1 inhibits the expression of type–I
IFN. This finding is in corroboration with previously reported inhibitory effects of NS1 on
the induction of type-I IFN [172, 175, 273, 358]. Next, in order to test if IFN-β has any
inhibitory effect on IL-23, mRNA expression of IL-23p19 was investigated in the
experimentally treated cells as above. As expected, delNS1 virus infection, as compared to
the PR8 virus infection, resulted in significant upregulation of IL23p19 in both the
macrophage types tested. While studying the effect of influenza virus on DC maturation,
significantly higher induction of both type-I interferon and IL-23p19 was also observed in
delNS1 virus infected cells as compared to the PR8 virus infected cells [274]. In the
previous study (Chapter III), it was observed that NS1, at least in part, was responsible for
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the inhibition of CHOP-10 in RAW cells. Those observations held true in the present study
as well. DelNS1 virus, as compared to the PR8 virus, induced significantly higher
expression of CHOP-10 in the RAW cells as well as in the primary alveolar macrophages.
Taken together these results support the possibility of the existence of a type-I interferon
independent mechanism that may involve CHOP-10.
Next, the effect of siRNA-mediated knock-down of CHOP-10 was investigated in
cells infected with delNS1 virus. The underlying hypothesis was that the CHOP-10
knockdown will lead to downregulation of delNS1 virus-induced IL-23p19 expression.
Results of this experiment supported the hypothesis that a CHOP-10 knock down caused
downregulation of IL-23p19 expression. My findings are in agreement with the previous
reports on the effect of CHOP-10 knockdown on IL23p19 expression. CHOP-10
knockdown in U937 cells, a human monocytic cell line, resulted in a substantial reduction
in the TG/LPS induced IL-23p19 expression as well as in response to Chlamydia
trachomatis infection [4]. Further, overexpression of CHOP-10 rescued, at least partially,
the IL23p19 expression in the PR8 virus infected cells. These results implied that CHOP10, at least in part, is responsible for influenza virus NS1 mediated down-regulation of IL23p19.
Results of in vivo experiments in mice further confirmed the primary hypothesis
and co-infection of bacteria and PR8 virus resulted in significant lower IL-23 and IL-17 as
compared to the delNS1virus infected cells. Similar inhibition of bacteria-induced IL-17
was observed when influenza virus-infected mice were superinfected with Streptococcus
pneumoniae [359]. Unexpectedly, although lower than the S. Ze alone infected animals,
mice infected with PR8 virus showed higher expression of IL23p19 and IL-17A as
82

compared to the delNS1 alone infected mice. A possible explanation could be that delNS1
virus replicate poorly in the type-I interferon competent cells [276] and bacterial coinfection results in the increased replication of the virus. Increased replication of the virus
was observed in the combined S. aureus and influenza infection possibly due to enhanced
cleavage of viral HA1 by streptococcal proteases [360]. Proteases derived from S. aureus
and concentrated in vitro can cleave the HA, supporting the hypothesis [361].
Unlike in vitro observations, IFN-β expression was lower in the delNS1 virus
infected mice. Also, while mice co-infected with delNS1 and bacteria showed a significant
difference in the induction of IFN-β, the induction was minimal in the all the treatment
groups relative to the control group. These results are intriguing and do not exclude the
role of type-I interferon in the influenza virus mediated subversion of IL23/IL17 pathway
as reported previously by Kudva et al., [300]. A possible explanation for the minimal
induction in virus infected mice could be that viral replication in the lung was not sufficient
to induce substantial IFN-β. It is also possible that IFN-β induction is time and dose
dependent. In the mouse model, it has been observed that while mutant viruses lacking
NS1 induce IFN-β early that peaks around 24 hrs, wild type virus does not induce
substantial levels of IFN-β during the first 24 hrs [362, 363]. Additionally, the difference
in the source of type-I IFN in lungs of mice infected with PR8 virus and delNS1 could also
contribute to our observation. Kallfass et al., reported that, while the primary source of
IFN-β in IAV lacking NS1 was infected epithelial cells and CD11c- macrophage cells, in
the lungs of mice infected with wild type virus , IFN-β was mainly produced from CD11c+
cells and the contribution of epithelial cells was minimal [363]. Since mice were infected
under anesthesia, it is possible that most of the inoculum was deposited in the lungs and
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hence there was not much contribution from the epithelial cells. However, studying the
effect of time and dose of viruses on the kinetics of IFN-β induction in vivo could provide
better insight and needs to be investigated further.
Although, there are certain limitations and, some areas need further investigation,
results from this study support the hypothesis that influenza virus NS1 mediated inhibition
of CHOP-10 leads to the inhibition of respiratory IL-23/IL17 axis of innate immune
response. However, the present study does not exclude the possible role of type-I IFN in
the regulation of IL-23/IL17 pathway during influenza infection.
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Table 4.1: List of Taqman® assays used in this study

Target
CHOP-10
IFN-β
IL-23p19
IL-17
GAPDH

Gene aliases
DDIT3, Gadd153
IFNb1
IL-23a
IL-17A
GAPD
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Taqman ®Assay ID
Mm01135937_g1
Mm00439552_s1
Mm01160011_g1
Mm00439618_m1
Mm99999915_g1

Figure 4.1: Relative expression of type-I interferon mRNA in macrophage cells
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with
Thapsigargin (0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A
virus strain PR/8/34; delNS1: Influenza A virus isogenic to PR8 but lacks NS1
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Figure 4. 2: Relative expression of IL-23p19 mRNA in macrophage cells
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with
Thapsigargin (0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A
virus strain PR/8/34; delNS1: Influenza A virus isogenic to PR8 but lacks NS1
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Figure 4.3: Relative expression of CHOP-10 mRNA in macrophage cells
Mock: cell culture supernatant from non-infected Vero cells; Positive: Treated with Thapsigargin
(0.025μM) and LPS (100ng/mL) for last 7 hrs of the culture; PR8: Influenza A virus strain PR/8/34;
delNS1: Influenza A virus isogenic to PR8 but lacks NS1
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Figure 4.4: Effect of CHOP-10 overexpression on IL-23p19 mRNA expression

pCHOP-10+Mock: cells transfected with CHOP-10 overexpression plasmid then mock infected
pCHOP-10+PR8: cells transfected with CHOP-10 overexpression plasmid then infected with PR8
virus
pCMV+PR8: cells transfected with empty control vector then infected with PR8 virus
pCMV+Mock: cells transfected with empty control vector then mock infected
**= p<0.001; ***= P<0.0001
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Figure 4.5: Effect of CHOP-10 knockdown on IL-23p19 mRNA expression
RAW+delNS1: Non-transduced RAW cells infected with delNS1
CHOP-10-siRNA+delNS1: cells transduced with CHOP-10 siRNA lentivirus then infected with
delNS1 virus
Sic+delNS1 cells transduced with non-target control siRNA lentivirus then infected with delNS1 virus
*=P<0.05; **=P<0.001
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Figure 4.6: Relative expression of IL23p19 mRNA in mouse lung
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and Zoo+PR8).
cDNA was prepared from RNA extracted from BAL cells and Real-time PCR was
performed. Relative quantitation was done Δ ΔCT method.
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Figure 4.7: Relative expression of IL-17A mRNA in mouse lung
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and Zoo+PR8).
cDNA was prepared from RNA extracted from BAL cells and Real-time PCR was
performed. Relative quantitation was done Δ ΔCT method.
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Figure 4.8: Relative expression of IFN-β mRNA in mouse lung
Mice were inoculated intranasally with Saline (Control), virus diluted in saline (delns1 or
PR8), or S. Ze in combination with either delNS1 or PR8 virus (Zoo+delNS1 and
Zoo+PR8). cDNA was prepared from RNA extracted from BAL cells and Real-time PCR
was performed. Relative quantitation was done Δ ΔCT method.
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CHAPTER 5
Intranasal administration of recombinant IL-23 protects mice from lethal coinfection of influenza A and Streptococcus zooepidemicus co-infection
5.1. Introduction
Influenza A virus (IAV) infection is one of the major respiratory disease worldwide.
Although, some IAV are sufficiently virulent to cause mortality in the host, secondary
bacterial infections appear to be major contributors in the influenza associated deaths.
During the influenza pandemic of 1918 that caused the death of about 40 to 50 million
persons [214] while viral pneumonia killed many healthy young persons, most of the deaths
were due to secondary bacterial pneumonia [225]. Bacterial infection during influenza
virus infection can be either concurrent with the virus infection or subsequent to influenza
virus infection. Concurrent bacterial and influenza pneumonia, although less frequent, have
a worse outcome than sequential infection [364]. Concurrent influenza virus/bacterial
infection is multifactorial and involves interaction between the host, bacteria and virus,
whereas post-influenza infection involves interaction between host and bacteria only.
Therefore, in post-influenza pneumonia the host response will be against bacterial
pathogens only, but in concurrent infection the host will respond to the virus as well as the
bacterial pathogen. These differences could affect the outcome and are important in
deciding the therapeutic regimen for treating influenza pneumonia [207].
Vaccination against seasonal influenza has been shown to reduce influenza
incidences greatly. Epidemics of seasonal influenza have been attributed to random single
point mutations. Current advances in surveillance and epidemiological modeling could
help in predicting these vaccine strains and allow satisfactory vaccine design in advance.
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However, pandemic strains of IAV arise due to genetic shifts and therefore difficult to
predict. Hence, effective therapeutic interventions remain important especially to prevent
secondary bacterial complication, which is a major contributor in pandemic deaths.
Antibiotics, as well as antiviral, have been used with limited success. Despite the
availability of antibiotics, bacterial pneumonia was involved in almost two-thirds of fatal
cases during the influenza pandemic of 1957. Inhibitors of viral replication have also been
investigated. Neuraminidase inhibitors significantly improved the survival of mouse form
pneumonia following influenza [365]. There is a relatively small window, however, in
which neuraminidase inhibitors can reduce viral replication and missing that time-window
will result in failure to prevent mortality in mice with influenza complicated by bacterial
pneumonia [366]. Survival of mice with post-influenza bacterial pneumonia did not
improve after treatment with Rimantadine [256]. Moreover, efficacy of these inhibitors in
concurrent influenza and bacterial infection has not been investigated. Development of
antibiotic resistant bacteria and antiviral-resistant influenza viruses further limit the use of
these therapeutics.
A classical explanation for increased secondary bacterial infection during influenza
has been the mechanical damage to the respiratory tract. However, altered host respiratory
innate immune response has begun to be appreciated. Cytokines are an integral part of the
host innate immune system, a broadly reactive defense mechanism of the host, which acts
as the first line of defense against a variety of invading pathogens. IL-23 is a recently
identified cytokine that has been shown to be important in the respiratory innate immune
response. IL-23, in concert with IL-17, constitutes a newly identified innate immune
pathway. The host IL-23/IL-17 pathway has been shown to play a critical role in the
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clearance of many respiratory bacterial pathogens. However, its role during influenza and
bacterial co-infection has not been investigated much. Thus, it was hypothesized that
inhibition of respiratory IL23/IL17 pathway by influenza virus predisposes the host for
secondary bacterial infection and restoring the respiratory IL-23 by rIL-23 administration
will increase the clearance of bacteria and reduce the pathogenesis of influenza. In order to
test this hypothesis, effect of restoration of respiratory IL-23 by intranasal administration
was studied in a mouse model of concurrent influenza and bacterial infection. To study the
effect of IL-23 restoration on clearance of virus and bacteria, weight loss of the animals
and survival analysis was performed.
5.2. Materials and methods
Infectious agents: PR/8/34 strain (PR8) of IAV and an isogenic recombinant virus lacking
NS1 (delNS1) as described in the previous chapters (chapter III) were used in the current
study. For bacterial co-infection S.ze strain 7e was used. Bacteria were cultured and
inoculum was prepared as described in chapter IV.
Animals: Six-eight week old female CD-1 mice were purchased from a commercial
supplier (Harlan). On arrival mice were housed in microisolater cages with an ad libitum
supply of food and water. Mice were acclimatized for one week before infection and
examined daily for any signs of stress or illness following the guidelines of Institutional
Animal Care and Use Committee (IACUC) at University of Kentucky (fig 5.4, table 5.1).
All the animal work was approved by IACUC at University of Kentucky.
Inoculation of mice and rIL-23 administration: Mice were sedated with
ketamine/xylazine administered by intraperitoneal injection. Once sedated mice were held
upright by holding from the loose scruff at the neck. Inoculum was prepared to contain
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approximately 1x106 CFU of bacteria and 1000 TCID50 units of PR8 virus in a final
volume of 60µL normal saline. A small drop of inoculum was placed near each nostril so
that mice involuntarily inhaled the inoculum. The inoculum was instilled from alternating
the nostrils so that whole inoculum (60µL) was divided equally between two nostrils. Mice
(n=18/group) were then assigned randomly to either rIL-23 or vehicle group that received
PBS that was used to resuspended IL-23. Immediately after the viral/bacterial inoculation,
a total of 3 µg rIL-23 in 20µl PBS was administered intranasally to the rIL-23 treatment
group and 20µL PBS was administered intranasally to the vehicle only group as described
for the inoculum. Investigator was blinded for which group received which treatment until
data were collected and analysis was completed.
BAL Fluid collection: Mice were euthanized 72 hrs post infection and BAL fluid was
collected aseptically with sterile intra-tracheal catheterization as described in chapter IV.
A total of 1 mL sterile normal saline was instilled in the lungs and aspirated. The aspirated
fluid was re-infused and aspirated for a total of three times. BAL fluid was centrifuged at
600g/5min and cell-free BAL was transferred to sterile microcentrifuge tubes as single use
aliquots and frozen at -80○C.
Determination of bacterial and viral load in the lungs: Lung bacterial and viral burden
was determined from the BAL fluid of co-infected mice. In order to determine the bacterial
burden, 10 fold serial dilutions of cell free BAL fluid were plated in duplicate onto
Columbia CNA agar supplemented with 5% horse blood. Plates were incubated at
37○C/5% CO2 for 24 hrs before counting the number of colonies and recording the results
as CFU/mL.
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Lung virus titer was determined by IAV matrix gene-based quantitative real-time
PCR. Viral RNA was extracted from 50ul cell-free BAL fluid using the magmax™ 96 viral
nucleic acid extraction kit (Ambion AM-1836) following manufacturers instruction.
Quantitative real-time PCR was performed using 1-step RT-PCR kit on ABI 7500 platform
using the primer probes described previously (CDC REF #I-007-05). Sequence of primer
and probes is provided in Table 5.2.
Data analysis: Pathogen burden and weight loss data was analyzed using students T-test
with Welch’s correction using GraphPad (Prism6) statistical software. Survival fractions
of the two groups were estimated using Kaplan-Meier method and survival curves were
compared by log-Rank (Mentel-Cox) test and Gehan-Breslaw-Wilcoxon test using
GraphPad statistical software (Prism6).
5.3. Results
Effect of IL-23 administration on bacterial and viral burden in the lungs of ci-infected
mice: Mice were observed daily for clinical signs and scored following the guidelines
provided by IACUC (Table 5.1 and Fig. 5.4). Pronounced clinical signs of disease
characterized by ruffled fur, lethargy, hunched posture and labored breathing were
displayed by both the treatment groups of mice as early as day 2. However, subsequent
clinical signs were more pronounced in the vehicle only group and some of the mice in
rIL-23 treatment group started to recover by day 6 onwards.
Since IL-23 treated mice showed less severe clinical signs as compared to the
vehicle only treated mice, it was hypothesized that treated mice would have improved
clearance of bacteria and virus from the lungs. As mortality started on day three PI, we
chose 72 hrs PI time point to assess the bacterial and viral burden in the two groups. Results
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of bacterial load in the BAL fluid are presented in Fig 5.1. Although statistically nonsignificant (P=0.5490), bacterial count in the IL-23 treated mice trended towards lower
side as compared to the non-treated mice suggesting that IL-23 might have a role in the
clearance of bacteria.
Viral burden was determined in the cell free BAL fluid by using quantitative realtime PCR. Results of the quantitative real-time PCR (Fig 5.1B) are presented as threshold
cycle (CT) value. There was no statistically significant difference in viral load between two
groups (P=0.3066), suggesting that IL-23 had no effect on viral clearance.
Effect of intranasal rIL-23 treatment on weight loss in co-infected mice: In order to
determine whether IL-23 could affect the clinical outcome of the co-infection, we
compared the weight loss of the treated and non-treated mice. Weight of each mouse was
recorded every 24 hrs and percent weight loss was calculated respective to weight on day
zero. Mice with a weight loss of ≥ 25% of day zero weight were euthanized and considered
dead for data analysis purposes. Mean percent weight loss of mice from each group are
presented in Fig 5.2. As expected, mice treated with PBS (vehicle), as compared to the rIL23 treated mice, showed higher weight loss. Weight loss was statistically significant as
early as day two (p=0.0005), and by day six all the mice were dead in the non-treated
vehicle group.
Effect IL-23 treatment on survival of co-infected mice: Next we wanted to determine
whether intranasal rIL-23 treatment affects the survival of mice. Age and sex matched 6-8
week old mice were randomly allotted to either rIL-23 treated group or a control group
treated with vehicle only (PBS). Each mouse of both the group was observed daily and
clinical scores were recorded as per the IACUC guidelines (Table 5.1). Any mouse
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showing a cumulative score of ≥6 or a score of three on a single category was euthanized
(IACUC guideline, Fig 5.4) and considered dead for data analysis purposes. Also, any
mouse showing ≥ 25% of weight loss of day zero weight was euthanized and considered
dead for data analysis purpose. Results of mortality are presented in Fig 5.3. First death
was observed in the rIL-23 treated group on day 3. However, later on mortality was more
pronounced in non-treated group and by day 6, all the mice in non-treated group were
succumbed to death. On the other hand, 50% (9/18) of the rIL-23 treated mice were
surviving on day 6. Most of the surviving mice either did not show any further weight loss
or showed a minimal weight loss suggesting recovery. Survival curve analysis showed a
highly significant difference with a p-value of 0.0015 and 0.0069 in Log-rank (Mentelcox) and Gehan-Breslaw-Wilcoxon tests, respectively, and the mean death time in the
treated group was prolonged by 1 day.
5.4. Discussion
Influenza infection is a leading cause of death worldwide. However, most of the
deaths associated with influenza have been ascribed to the secondary bacterial infection.
Secondary bacterial infection associated with influenza may either be due to concurrent
infection or follow a preceding influenza infection. As bacterial pneumonia often ensues
3-7 day post-influenza infection, most of the studies have used a sequential model of
secondary bacterial infection where bacterial inoculations were performed up to seven days
after preceding influenza challenge. However, although less frequent, concurrent influenza
and bacterial infections involve more complex interactions of host, virus, and bacteria than
the sequential infection and often result in more serious outcome than sequential infection
[364]. Furthermore, some of the secondary bacterial invaders during influenza infection
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are opportunistic pathogens commonly present in the upper respiratory tract of humans as
well as animals which could lead to secondary infection during influenza. Therefore, in the
current study a concurrent infection model was used to investigate the therapeutic potential
of rIL-23 on influenza-associated secondary bacterial infections. Since S. zoo is a
commonly associated secondary invader during equine influenza, the overreaching goal of
the study was to investigate the effect of rIL-23 supplementation on outcome secondary S.
zoo infection during equine influenza infection. However, recombinant equine IL-23 is not
available yet, therefore, we tested our hypothesis in the mouse model. Mouse has been
successfully used as a model for S. zoo by Dr. P Timoney at Gluck equine research center.
Furthermore, the PR8 strain of influenza virus is well adapted to the mouse model and has
been used extensively to study the pathogenesis and immune response against influenza.
IL-23 is a recently identified member of IL-6 family of cytokines that is important
in the induction and maintenance of Th17 cells that secrete IL-17. IL-17 is an early
proinflammatory cytokine that mediates host defense against several respiratory bacterial
pathogens. Although there are reports on using intranasal rIL-23 as a therapeutic
intervention against respiratory bacterial infections, it has not been investigated much
during influenza and bacterial co-infection. There is only one study that investigated the
effect of restoration of IL23 in the lungs of influenza and bacterial co-infection in which
Adenovirus expressing rIL-23 was found to improve the clearance of bacteria in S.
pneumoniae and influenza co-infected mice [300]. Thus, current study appears to be the
first to utilize intranasal rIL-23 as therapeutic intervention during concurrent influenza and
bacterial co-infection.
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The hypothesis in the current study was that rIL-23 treatment will improve the
clearance of virus and bacteria. Unexpectedly, there was no significant difference between
respiratory viral load between rIL-23 and control animals. Likewise, although bacterial
counts were lower in the treated mice, they were statistically not significant. In contrast to
the present study, Kudva et al., observed that overexpression of IL-23 in the lungs of mice
resulted in improved clearance of virus as well as bacteria [300]. It should be noted,
however, that authors in that study used a sequential model of infection where bacterial
infection was performed at day six post-influenza infection. It is possible that during this
time there was already some repair of the tissue damage caused by influenza virus resulting
in decreased adherence of bacteria. Additionally, since adenovirus was used to express the
IL-23, it would be difficult to determine the exact level of IL-23 in the lungs. Furthermore,
timing and duration of the IL-23 administration may have important implications on the
outcome. One of the limitations of the present study is that only a single intranasal dose of
rIL-23 concurrent with the infection was used. In the case of adenoviral overexpression
levels of IL-23 could be maintained during the infection and may have a significant effect
on the clearance of virus as well as bacteria. It is possible that a subsequent dose may help
in maintaining the levels of IL-23 in the lungs and further improve the clearance of virus
and bacteria and needs to be investigated.
As expected, rIL-23 treated mice, as compared to the vehicle only treated mice,
showed less severe signs of disease, less weight loss and improved survival suggesting that
intranasal rIL-23 could limit the pathology of co-infection. One possible mechanism could
be the suppression of the early strong inflammatory response (cytokine storm) that plays
an important role in the pathogenesis of influenza. It was recently found that adenovirus102

mediated overexpression of IL-23 resulted in the decreased lung inflammation in influenza
and S. pneumoniae co-infected mice [300]. Additionally, improved survival of rIL-23
treated mice could also be due to increased tolerance of the host for infection due to
accelerated tissue repair and homeostasis. Recently, it was observed that, despite normal
anti-bacterial immune response, hosts were susceptible to lethal secondary bacterial
infection in influenza infected mice due to impaired ability to tolerate respiratory tissue
damage [102]. Studies with amphiregulin, a member of the family of epithelial growth
factors, revealed an important role in lung tissue homeostasis in the survival of influenza
and bacteria co-infected mice. While amphiregulin treatment did not affect the bacterial
and viral burden in co-infected mice, it resulted in decreased lung tissue damage and
significantly improved weight loss and the survival of co-infected mice [102]. IL-23 could
help in the repair of damaged respiratory tissue mediated by IL-22. IL-22 is important for
the modulation of tissue responses during inflammation, and it induces proliferative and
anti-apoptotic pathways, as well as anti-microbial molecules that help prevent tissue
damage and aid in its repair [367]. IL-23 has been shown to be critical in the differentiation
and proliferation of Th17 cells [368]. Also, IL-22 has been reported to be robustly secreted
by Th17 cells in IL-23 dependent fashion [369]. Although the extent of tissue damage was
not evaluated between IL-23 treated and control groups and needs to be investigated, it
seems plausible that the difference in tissue repair could have resulted in improved
tolerance in the rIL-23 treated mice.
In the present study we observed that while IL-23, to some degree, helped in
clearance of bacteria in co-infected mice, it did not affect the viral clearance. Although, we
did not establish the underlying mechanism, we did observe that intranasal rIL-23
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administration, significantly improved the survival of co-infected mice. From our study,
we conclude that intranasal administration of rIL-23 has a beneficial effect during
concurrent bacterial and influenza virus co-infection and in the wake of emerging drug
resistant influenza viruses and bacteria, IL-23 could potentially be included as alternative
therapeutic intervention.
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Figure 5.1: Bacterial and viral burden in the lungs of influenza and S. ze co-infected mice
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation
mice were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). At 72 hr PI BAL fluid was
collected.Cell free BAL fluid was plated on CAN agar supplemented with 5% horse blood and colonies
were counted after 24 hr and bacterial burden (CFU/mL of BAL fluid) was determined (A). viral RNA
was extracted from cell free BAL fluid and Real-Time PCR CT values were used to compare the viral
burden.

A

105

B

Figure 5.2: Effect of intranasal rIL-23 administration on weight loss in influenza and S. ze co-infected
mice
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation mice
were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). Mice were weighed daily and weight
loss was calculated to as percent of day 0 weight. Data was analyzed by using t-test with Welch’s correction
using GraphPad Prism 6 software. (*= P<0.05; **= P<0.01; ***=P<0.0001)
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Figure 5.3: Effect of intranasal rIL-23 administration on survival of influenza and S. ze co-infected
mice
Mice were co-infected with PR8 virus and S. ze by intranasal inoculation. Immediately after inoculation
mice were intranasllly given recombinant IL-23 (rIL-23) or PBS (Vehicle). Mortality was recorded
andsurvival fractions were calculated. Survival curve comparison was performed using Prism 6.0
(GraphPad software) that uses Kaplan-Meier method to generate survival fractions and survival curves
are compared by log-Rank (Mentel-Cox) test and Gehan-Breslaw-Wilcoxon test. Two curves were
significantly different with P value 0.0015 and 0.0069 in Log-rank (Mentel-cox) and Gehan-BreslawWilcoxon tests, respectively.
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Figure 5.4: Treatment flow chart for mice with respiratory infections
From (IACUC, University of Kentucky)

Pain/Stress Score
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Score 0 for a category

Total score 1-6 and <3 for a single
category

No Intervention

No Intervention

Check daily

Recheck in 6-12 hours

Score 3 for a single category
or in multiple categories

Euthanasia

Table 5.1: Clinical scoring criteria for mice

Criteria/Score

0

1

2

3

Moving normally
around cage, not
hugging the sides of
the cage.

Stumbling , falling, or
hugging the sides of
the cage.

Writhing,
stumbling and/or
falling. OR
Movement only
when stimulated.

No movement.

Respiration

Normal rate with no
audible respiratory
sounds to naked ear

Mild “chattering” or
“snoring”

Moderate
“chattering” or
“snoring”

Labored
breathing ,
increased
respiratory rate

Behavior

Normal cage
exploration, normal
food and water
consumption, animal
calm in cage.
Previously social
animal still social.

Minimal exploration,
increased or
decreased food and/or
water consumption.

No cage
exploration,
hunched posture,
anorexic for 24 hrs.

No cage
exploration,
hunched
posture,
piloerection,
anorexic, or
moribund
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Locomotion

Previously social
animal has become
withdrawn or
aggressive.

Total

Table 5.2: Primer and probe sequence for influenza virus real-time PCR
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Primer/probe
InfA Forward
InfA Reverse
InfA Probe

Sequence (5’>3’)
GAC CRA TCC TGT CAC CTC TGA
C
AGG GCA TTY TGG ACA AAK CGT
CTA
FAM-TGC AGT CCT CGC TCA CTG
GGC ACG-BHQ1

Target IAV gene
Matrix (M1)

Final Concentration
800nM

Matrix (M1)

800nM

Matrix (M1)

200nM

CHAPTER 6
General discussion and conclusions
The goal of the present study was to identify the possible viral and host factors that
predispose the host to secondary bacterial infection during influenza virus infection. The
major hypothesis was that influenza virus NS1 protein-mediated inhibition of an ER stress
transcription factor mediates the inhibition of the respiratory IL-23/IL17 axis of innate
immune response. I tested my hypothesis in vitro using mouse macrophage cell line as well
as primary alveolar macrophage cells and in vivo using mouse model. Although, there are
certain areas that need to be further investigated, results from the study support our
hypothesis.
In the first part of the study, effect of NS1 protein on ER stress response of mouse
macrophages was studied in vitro. Results of this study support the hypothesis that
influenza virus NS1 mediates differential activation of the ER stress response. While
influenza virus induced activation of chaperones, it inhibited the induction of CHOP-10.
Since influenza viruses rely heavily on the host cellular machinery for their protein
synthesis, it appears counterintuitive that virus would not induce ER stress.
Why would influenza virus inhibit ER stress? ER stress response is an evolutionary
conserved host response that is used to resolve the excessive protein load on the ER. By
activating three arms of UPR, the host cell tries to restore the ER homeostasis. It seems
that influenza virus cleverly inhibits the PERK and IRE1 branches, but does not inhibit the
ATF6 branch. While activation of PERK leads to the EIF2α phosphorylation that shuts
down the global protein synthesis, activation of IRE1 branch leads to induction of
transcription factors involved in the ER-associated degradation. Thus, activation of these
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branches would limit the viral protein synthesis. Additionally, EIF2α phosphorylation
leads to selective transcription of ATF4 that induces CHOP-10, a pro-apoptotic factor
induced during the ER stress. While apoptosis may help in the viral spread and
pathogenesis, premature cellular death would be detrimental for virus replication.The
ATF6 branch activates transcription of ER chaperones that could promote viral replication
by increasing the folding capacity of the ER. Indeed, ER chaperone protein Erp57 is
reported to be crucial in the folding of influenza virus HA [315]. Therefore, the differential
activation of the UPR pathway by influenza virus in the present study would support
influenza viral replication.
Recently, a type-I IFN mediated mechanism for IL-23 inhibition has been reported,
but influenza virus is known to inhibit type-I IFN. So, an interferon independent
mechanism was speculated. The hypothesis was that influenza virus NS1 protein-mediated
inhibition of CHOP-10 results in the inhibition of IL-23 expression. The hypothesis was
tested in vitro in mouse macrophage cells and in vivo using a mouse model. Although in
vivo results in the present study could not exclude the possibility of type-I IFN dependent
mechanism, results from the in vitro study do suggest the presence of type-I interferon
independent mechanism mediated by CHOP-10. Recent findings of the critical role of
CHOP-10 in IL-23 regulation in human dendritic cells [4], further support our hypothesis.
Innate immune responses are mainly triggered by the PRRs. Then why would ER
stress influence the innate immune response? PRR act as sentinels to sense the
environmental danger signals such as extracellular microbial products and products of
stressed or damaged tissues such as PGE2, ATP and urate [370]. Similar to the PRR,
activation of UPR may serve as a counterpart to the external danger signal detection system
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especially in the case of intracellular pathogens such as virus and intracellular bacteria. By
activating UPR, cell may sense the presence of intracellular pathogens. Thus, integrating
the PRR signaling with UPR activation would favor a failsafe mechanism for the host to
detect danger signals especially in the case of intracellular pathogens.
Why would ER stress signal induce IL-23? In a review of IL-23 and IL-17 immune
pathway, Mckenzie et al., [370] suggested that IL-23 is critical in driving the early immune
response to infection. IL-23 rapidly induces IL-17 from Th17 cells that allow early
recruitment of phagocytic cells such as neutrophils and macrophages to provide early
clearance of pathogens [370]. Therefore, inhibition of the respiratory IL-23/IL-17 response
could be important for the replication and pathogenesis of influenza.
Having found that influenza virus inhibits the IL23/IL17 pathway, it was speculated
that restoration of IL-23 in the lungs would reduce the pathogenesis of influenza virus
infection. Secondary bacterial infections are common during influenza, and IL-23 has been
shown to provide protection from a variety of respiratory bacterial pathogens. Therefore,
the hypothesis was that the restoration of respiratory IL-23/IL-17 innate immune pathway
in the lungs would help in clearance of the pathogens and protect the host from lethal coinfection of influenza and bacteria. In order to test this hypothesis, intranasal rIL-23
administration was used to restore the respiratory IL-23/IL-17 pathway in a mouse model
of concurrent influenza and bacterial infection. Although, rIL-23 administration had no
effect on viral clearance, it did help in the clearance of bacteria, albeit to a limited extent.
However, a notable finding was that a single dose of intranasal IL-23 significantly
improved the survival of co-infected infected mice.
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How could rIL-23 administration protect the host without significantly affecting
the pathogen clearance? Protection of the host can be achieved in three ways: avoidance,
resistance, and tolerance [371]. While avoidance reduces the risk of exposure to infectious
agents, resistance reduces pathogen burden once the infection is established [371]. On the
other hand, tolerance increases the fitness of the host by reducing the negative impact of
an infection without directly affecting the pathogen load [372-374]. It is possible that IL23, by inducing an additional mediator such as IL-22, induces a rapid tissue repair and
could increase host tolerance. Indeed, recent findings by Jamieson et al., support this idea.
They found that influenza virus infection enhanced susceptibility to secondary bacterial
infection, even when bacterial infection was controlled by the immune system [102].
However, it should be noted that we have used a single intranasal dose of rIL-23, and we
could not completely determine whether the protective effect of IL-23 was due to increased
immune response or the tolerance.
Based on findings from current study and previously published reports, a working
model for how influenza virus NS1-mediates inhibition of CHOP-10 and how this leads to
inhibition of IL-23 and increases the susceptibility of the host to secondary bacterial
infection has been presented in Fig 6.1.
In conclusion, this dissertation demonstrates for the first time that influenza virus NS1
protein is the viral factor that is involved in differential activation of cellular ER stress
response. Additionally, this study also provides the evidence for the first time that influenza
virus mediated inhibition of IL-23 is mediated by ER stress-induced transcription factor
CHOP-10.The study also provides valuable insights on the increased susceptibility of
bacterial infection during influenza that could be utilized for future therapeutic targets
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against influenza virus. This study also shows that IL-23 could be used as potential
therapeutic agent to reduce influenza-associated mortality.
Limitations and future directions: This dissertation provide evidence to support the
primary hypothesis that influenza virus NS1-mediated inhibition of CHOP-10 mediates the
inhibition of IL-23/IL-17 pathway of respiratory innate immune response which results in
enhanced bacterial susceptibility during influenza. However, the study did not identify the
exact mechanism of inhibition and proposed mechanism is substantially built upon findings
in different cell type. Therefore, future research needs to be done to confirm the proposed
model in alveolar macrophages. In the current study, effect of single intranasal dose rIL23 administration on pathogen clearance was investigated in an immunocompetent host.
To further delineate the role of IL-23 in protective immune response, future research using
IL23 knockout host could further confirm the protective roles of IL-23. Also,
characterization of innate immune cells, cytokines and tissue repair after IL-23
administration would be useful in understanding the IL-23/IL-17 immunity against
secondary bacterial infections during influenza infection.
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Figure 6.1: Model for influenza virus NS1-mediated inhibition of IL-23
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